-
1
-
-
84862758175
-
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
-
22713970,; PMID
-
Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012; 13:411-24; PMID:22713970; http://dx.doi.org/10.1038/nrm3376
-
(2012)
Nat Rev Mol Cell Biol
, vol.13
, pp. 411-424
-
-
Gibson, B.A.1
Kraus, W.L.2
-
2
-
-
33745867638
-
Poly(ADP-ribose): novel functions for an old molecule
-
16829982,; PMID
-
Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7:517-28; PMID:16829982; http://dx.doi.org/10.1038/nrm1963
-
(2006)
Nat Rev Mol Cell Biol
, vol.7
, pp. 517-528
-
-
Schreiber, V.1
Dantzer, F.2
Ame, J.C.3
de Murcia, G.4
-
3
-
-
0033198919
-
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
-
10455009,; PMID
-
D‘Amours D, Desnoyers S, D’Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342 (Pt 2):249-68; PMID:10455009; http://dx.doi.org/10.1042/0264-6021:3420249
-
(1999)
Biochem J
, vol.342
, pp. 249-268
-
-
D‘Amours, D.1
Desnoyers, S.2
D’Silva, I.3
Poirier, G.G.4
-
4
-
-
0018906390
-
(ADP-ribose)n participates in DNA excision repair
-
6243744,; PMID
-
Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980; 283:593-6; PMID:6243744; http://dx.doi.org/10.1038/283593a0
-
(1980)
Nature
, vol.283
, pp. 593-596
-
-
Durkacz, B.W.1
Omidiji, O.2
Gray, D.A.3
Shall, S.4
-
5
-
-
25444463296
-
Poly(ADP-ribose). The most elaborate metabolite of NAD+
-
16156780,; PMID
-
Burkle A. Poly(ADP-ribose). The most elaborate metabolite of NAD+. FEBS J 2005; 272:4576-89; PMID:16156780; http://dx.doi.org/10.1111/j.1742-4658.2005.04864.x
-
(2005)
FEBS J
, vol.272
, pp. 4576-4589
-
-
Burkle, A.1
-
6
-
-
84903278353
-
New PARP targets for cancer therapy
-
24898058,; PMID
-
Vyas S, Chang P. New PARP targets for cancer therapy. Nat Rev Cancer 2014; 14:502-9; PMID:24898058; http://dx.doi.org/10.1038/nrc3748
-
(2014)
Nat Rev Cancer
, vol.14
, pp. 502-509
-
-
Vyas, S.1
Chang, P.2
-
7
-
-
77951023118
-
Toward a unified nomenclature for mammalian ADP-ribosyltransferases
-
20106667,; PMID
-
Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 2010; 35:208-19; PMID:20106667; http://dx.doi.org/10.1016/j.tibs.2009.12.003
-
(2010)
Trends Biochem Sci
, vol.35
, pp. 208-219
-
-
Hottiger, M.O.1
Hassa, P.O.2
Luscher, B.3
Schuler, H.4
Koch-Nolte, F.5
-
8
-
-
84933277911
-
The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy
-
25220415,; 34(26):3349-56; PMID
-
Li M, Yu X. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene 2015; 34(26):3349-56; PMID:25220415; http://dx.doi.org/10.1038/onc.2014.295
-
(2015)
Oncogene
-
-
Li, M.1
Yu, X.2
-
9
-
-
84886728595
-
Poly(ADP-ribosyl)ation in carcinogenesis
-
23714734,; PMID
-
Masutani M, Fujimori H. Poly(ADP-ribosyl)ation in carcinogenesis. Mol Aspects Med 2013; 34:1202-16; PMID:23714734; http://dx.doi.org/10.1016/j.mam.2013.05.003
-
(2013)
Mol Aspects Med
, vol.34
, pp. 1202-1216
-
-
Masutani, M.1
Fujimori, H.2
-
10
-
-
84886723521
-
Poly(ADP-ribose): PARadigms and PARadoxes
-
23290998,; PMID
-
Burkle A, Virag L. Poly(ADP-ribose): PARadigms and PARadoxes. Mol Aspects Med 2013; 34:1046-65; PMID:23290998; http://dx.doi.org/10.1016/j.mam.2012.12.010
-
(2013)
Mol Aspects Med
, vol.34
, pp. 1046-1065
-
-
Burkle, A.1
Virag, L.2
-
11
-
-
84865731753
-
The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease
-
22921416,; PMID
-
Bai P, Canto C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 2012; 16:290-5; PMID:22921416; http://dx.doi.org/10.1016/j.cmet.2012.06.016
-
(2012)
Cell Metab
, vol.16
, pp. 290-295
-
-
Bai, P.1
Canto, C.2
-
12
-
-
84865737317
-
Role of PARP inhibitors in cancer biology and therapy
-
22788767,; PMID
-
Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012; 19:3907-21; PMID:22788767; http://dx.doi.org/10.2174/092986712802002464
-
(2012)
Curr Med Chem
, vol.19
, pp. 3907-3921
-
-
Davar, D.1
Beumer, J.H.2
Hamieh, L.3
Tawbi, H.4
-
13
-
-
84902322535
-
Poly(ADP-ribose): an organizer of cellular architecture
-
24914234,; PMID
-
Leung AK. Poly(ADP-ribose): an organizer of cellular architecture. J Cell Biol 2014; 205:613-9; PMID:24914234; http://dx.doi.org/10.1083/jcb.201402114
-
(2014)
J Cell Biol
, vol.205
, pp. 613-619
-
-
Leung, A.K.1
-
14
-
-
84857891632
-
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
-
22391446,; PMID
-
Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev 2012; 26:417-32; PMID:22391446; http://dx.doi.org/10.1101/gad.183509.111
-
(2012)
Genes Dev
, vol.26
, pp. 417-432
-
-
Luo, X.1
Kraus, W.L.2
-
15
-
-
4344685333
-
The PARP superfamily
-
15273990,; PMID
-
Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26:882-93; PMID:15273990; http://dx.doi.org/10.1002/bies.20085
-
(2004)
Bioessays
, vol.26
, pp. 882-893
-
-
Ame, J.C.1
Spenlehauer, C.2
de Murcia, G.3
-
16
-
-
77950023283
-
PARP inhibition: PARP1 and beyond
-
20200537,; PMID
-
Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10:293-301; PMID:20200537; http://dx.doi.org/10.1038/nrc2812
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 293-301
-
-
Rouleau, M.1
Patel, A.2
Hendzel, M.J.3
Kaufmann, S.H.4
Poirier, G.G.5
-
17
-
-
78649336706
-
The DNA damage response: making it safe to play with knives
-
20965415,; PMID
-
Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40:179-204; PMID:20965415; http://dx.doi.org/10.1016/j.molcel.2010.09.019
-
(2010)
Mol Cell
, vol.40
, pp. 179-204
-
-
Ciccia, A.1
Elledge, S.J.2
-
18
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
21376230,; PMID
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
20
-
-
70350504453
-
The DNA-damage response in human biology and disease
-
19847258,; PMID
-
Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461:1071-8; PMID:19847258; http://dx.doi.org/10.1038/nature08467
-
(2009)
Nature
, vol.461
, pp. 1071-1078
-
-
Jackson, S.P.1
Bartek, J.2
-
21
-
-
36749022214
-
The DNA damage response: ten years after
-
18082599,; PMID
-
Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007; 28:739-45; PMID:18082599; http://dx.doi.org/10.1016/j.molcel.2007.11.015
-
(2007)
Mol Cell
, vol.28
, pp. 739-745
-
-
Harper, J.W.1
Elledge, S.J.2
-
22
-
-
84919400644
-
Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3
-
25017100,; PMID
-
Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F. Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp Cell Res 2014; 329:18-25; PMID:25017100; http://dx.doi.org/10.1016/j.yexcr.2014.07.003
-
(2014)
Exp Cell Res
, vol.329
, pp. 18-25
-
-
Beck, C.1
Robert, I.2
Reina-San-Martin, B.3
Schreiber, V.4
Dantzer, F.5
-
23
-
-
70349778173
-
Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
-
19743897,; PMID
-
Papeo G, Forte B, Orsini P, Perrera C, Posteri H, Scolaro A, Montagnoli A. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 2009; 19:1377-400; PMID:19743897; http://dx.doi.org/10.1517/13543770903215883
-
(2009)
Expert Opin Ther Pat
, vol.19
, pp. 1377-1400
-
-
Papeo, G.1
Forte, B.2
Orsini, P.3
Perrera, C.4
Posteri, H.5
Scolaro, A.6
Montagnoli, A.7
-
24
-
-
84863693493
-
The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
-
22683995,; PMID
-
Ali AA, Timinszky G, Arribas-Bosacoma R, Kozlowski M, Hassa PO, Hassler M, Ladurner AG, Pearl LH, Oliver AW. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat Struct Mol Biol 2012; 19:685-92; PMID:22683995; http://dx.doi.org/10.1038/nsmb.2335
-
(2012)
Nat Struct Mol Biol
, vol.19
, pp. 685-692
-
-
Ali, A.A.1
Timinszky, G.2
Arribas-Bosacoma, R.3
Kozlowski, M.4
Hassa, P.O.5
Hassler, M.6
Ladurner, A.G.7
Pearl, L.H.8
Oliver, A.W.9
-
25
-
-
0038583869
-
Spatial and temporal cellular responses to single-strand breaks in human cells
-
12748298,; PMID
-
Okano S, Lan L, Caldecott KW, Mori T, Yasui A. Spatial and temporal cellular responses to single-strand breaks in human cells. Mol Cell Biol 2003; 23:3974-81; PMID:12748298; http://dx.doi.org/10.1128/MCB.23.11.3974-3981.2003
-
(2003)
Mol Cell Biol
, vol.23
, pp. 3974-3981
-
-
Okano, S.1
Lan, L.2
Caldecott, K.W.3
Mori, T.4
Yasui, A.5
-
26
-
-
84861231399
-
The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art
-
22469522,; PMID
-
De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012; 84:137-46; PMID:22469522; http://dx.doi.org/10.1016/j.bcp.2012.03.018
-
(2012)
Biochem Pharmacol
, vol.84
, pp. 137-146
-
-
De Vos, M.1
Schreiber, V.2
Dantzer, F.3
-
27
-
-
0142009654
-
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
-
14500814,; PMID
-
El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 2003; 31:5526-33; PMID:14500814; http://dx.doi.org/10.1093/nar/gkg761
-
(2003)
Nucleic Acids Res
, vol.31
, pp. 5526-5533
-
-
El-Khamisy, S.F.1
Masutani, M.2
Suzuki, H.3
Caldecott, K.W.4
-
28
-
-
0031844311
-
XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage
-
9584196,; PMID
-
Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998; 18:3563-71; PMID:9584196
-
(1998)
Mol Cell Biol
, vol.18
, pp. 3563-3571
-
-
Masson, M.1
Niedergang, C.2
Schreiber, V.3
Muller, S.4
Menissier-de Murcia, J.5
de Murcia, G.6
-
29
-
-
84882724418
-
The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response
-
23964092,; PMID
-
Li M, Lu LY, Yang CY, Wang S, Yu X. The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response. Genes Dev 2013; 27:1752-68; PMID:23964092; http://dx.doi.org/10.1101/gad.226357.113
-
(2013)
Genes Dev
, vol.27
, pp. 1752-1768
-
-
Li, M.1
Lu, L.Y.2
Yang, C.Y.3
Wang, S.4
Yu, X.5
-
30
-
-
0034731455
-
Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins
-
11016934,; PMID
-
Pleschke JM, Kleczkowska HE, Strohm M, Althaus FR. Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint proteins. J Biol Chem 2000; 275:40974-80; PMID:11016934; http://dx.doi.org/10.1074/jbc.M006520200
-
(2000)
J Biol Chem
, vol.275
, pp. 40974-40980
-
-
Pleschke, J.M.1
Kleczkowska, H.E.2
Strohm, M.3
Althaus, F.R.4
-
31
-
-
34547225606
-
Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase
-
17548475,; PMID
-
Fisher AE, Hochegger H, Takeda S, Caldecott KW. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol Cell Biol 2007; 27:5597-605; PMID:17548475; http://dx.doi.org/10.1128/MCB.02248-06
-
(2007)
Mol Cell Biol
, vol.27
, pp. 5597-5605
-
-
Fisher, A.E.1
Hochegger, H.2
Takeda, S.3
Caldecott, K.W.4
-
32
-
-
84873130772
-
Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair
-
23319653,; PMID
-
Robu M, Shah RG, Petitclerc N, Brind'Amour J, Kandan-Kulangara F, Shah GM. Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair. Proc Natl Acad Sci U S A 2013; 110:1658-63; PMID:23319653; http://dx.doi.org/10.1073/pnas.1209507110
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 1658-1663
-
-
Robu, M.1
Shah, R.G.2
Petitclerc, N.3
Brind'Amour, J.4
Kandan-Kulangara, F.5
Shah, G.M.6
-
33
-
-
84869111403
-
PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1
-
23045548, et al.,; PMID
-
Pines A, Vrouwe MG, Marteijn JA, Typas D, Luijsterburg MS, Cansoy M, Hensbergen P, Deelder A, de Groot A, Matsumoto S, et al. PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1. J Cell Biol 2012; 199:235-49; PMID:23045548; http://dx.doi.org/10.1083/jcb.201112132
-
(2012)
J Cell Biol
, vol.199
, pp. 235-249
-
-
Pines, A.1
Vrouwe, M.G.2
Marteijn, J.A.3
Typas, D.4
Luijsterburg, M.S.5
Cansoy, M.6
Hensbergen, P.7
Deelder, A.8
de Groot, A.9
Matsumoto, S.10
-
34
-
-
41149149754
-
Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway
-
18054777,; PMID
-
Audebert M, Salles B, Calsou P. Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway. Biochem Biophys Res Commun 2008; 369:982-8; PMID:18054777; http://dx.doi.org/10.1016/j.bbrc.2007.11.132
-
(2008)
Biochem Biophys Res Commun
, vol.369
, pp. 982-988
-
-
Audebert, M.1
Salles, B.2
Calsou, P.3
-
35
-
-
33845657443
-
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
-
17088286,; PMID
-
Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006; 34:6170-82; PMID:17088286; http://dx.doi.org/10.1093/nar/gkl840
-
(2006)
Nucleic Acids Res
, vol.34
, pp. 6170-6182
-
-
Wang, M.1
Wu, W.2
Rosidi, B.3
Zhang, L.4
Wang, H.5
Iliakis, G.6
-
36
-
-
69849097500
-
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
-
19629035,; PMID
-
Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 2009; 28:2601-15; PMID:19629035; http://dx.doi.org/10.1038/emboj.2009.206
-
(2009)
EMBO J
, vol.28
, pp. 2601-2615
-
-
Bryant, H.E.1
Petermann, E.2
Schultz, N.3
Jemth, A.S.4
Loseva, O.5
Issaeva, N.6
Johansson, F.7
Fernandez, S.8
McGlynn, P.9
Helleday, T.10
-
37
-
-
59449101071
-
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
-
19103807,; PMID
-
Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K. PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol 2008; 183:1203-12; PMID:19103807; http://dx.doi.org/10.1083/jcb.200806068
-
(2008)
J Cell Biol
, vol.183
, pp. 1203-1212
-
-
Sugimura, K.1
Takebayashi, S.2
Taguchi, H.3
Takeda, S.4
Okumura, K.5
-
38
-
-
84877823968
-
Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation
-
23680151,; PMID
-
Li M, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell 2013; 23:693-704; PMID:23680151; http://dx.doi.org/10.1016/j.ccr.2013.03.025
-
(2013)
Cancer Cell
, vol.23
, pp. 693-704
-
-
Li, M.1
Yu, X.2
-
39
-
-
84915749291
-
PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair
-
25252691, et al.,; PMID
-
Hu Y, Petit SA, Ficarro SB, Toomire KJ, Xie A, Lim E, Cao SA, Park E, Eck MJ, Scully R, et al. PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov 2014; 4:1430-47; PMID:25252691; http://dx.doi.org/10.1158/2159-8290.CD-13-0891
-
(2014)
Cancer Discov
, vol.4
, pp. 1430-1447
-
-
Hu, Y.1
Petit, S.A.2
Ficarro, S.B.3
Toomire, K.J.4
Xie, A.5
Lim, E.6
Cao, S.A.7
Park, E.8
Eck, M.J.9
Scully, R.10
-
40
-
-
84860806404
-
Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1
-
22582261,; PMID
-
Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 2012; 336:728-32; PMID:22582261; http://dx.doi.org/10.1126/science.1216338
-
(2012)
Science
, vol.336
, pp. 728-732
-
-
Langelier, M.F.1
Planck, J.L.2
Roy, S.3
Pascal, J.M.4
-
42
-
-
84873524967
-
PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
-
23333033,; PMID
-
Langelier MF, Pascal JM. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 2013; 23:134-43; PMID:23333033; http://dx.doi.org/10.1016/j.sbi.2013.01.003
-
(2013)
Curr Opin Struct Biol
, vol.23
, pp. 134-143
-
-
Langelier, M.F.1
Pascal, J.M.2
-
43
-
-
24344454692
-
Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal
-
16140981,; PMID
-
Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: ‘PAR-laying’ NAD+ into a nuclear signal. Genes Dev 2005; 19:1951-67; PMID:16140981; http://dx.doi.org/10.1101/gad.1331805
-
(2005)
Genes Dev
, vol.19
, pp. 1951-1967
-
-
Kim, M.Y.1
Zhang, T.2
Kraus, W.L.3
-
44
-
-
38149057387
-
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites
-
18025084,; PMID
-
Haince JF, McDonald D, Rodrigue A, Dery U, Masson JY, Hendzel MJ, Poirier GG. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem 2008; 283:1197-208; PMID:18025084; http://dx.doi.org/10.1074/jbc.M706734200
-
(2008)
J Biol Chem
, vol.283
, pp. 1197-1208
-
-
Haince, J.F.1
McDonald, D.2
Rodrigue, A.3
Dery, U.4
Masson, J.Y.5
Hendzel, M.J.6
Poirier, G.G.7
-
45
-
-
38449088040
-
The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases
-
17981777,; PMID
-
Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci 2008; 13:3046-82; PMID:17981777; http://dx.doi.org/10.2741/2909
-
(2008)
Front Biosci
, vol.13
, pp. 3046-3082
-
-
Hassa, P.O.1
Hottiger, M.O.2
-
46
-
-
84864003593
-
Histone ADP-ribosylation facilitates gene transcription by directly remodeling nucleosomes
-
22547677,; PMID
-
Martinez-Zamudio R, Ha HC. Histone ADP-ribosylation facilitates gene transcription by directly remodeling nucleosomes. Mol Cell Biol 2012; 32:2490-502; PMID:22547677; http://dx.doi.org/10.1128/MCB.06667-11
-
(2012)
Mol Cell Biol
, vol.32
, pp. 2490-2502
-
-
Martinez-Zamudio, R.1
Ha, H.C.2
-
47
-
-
80052172007
-
Histone ADP-ribosylation in DNA repair, replication and transcription
-
21741840,; PMID
-
Messner S, Hottiger MO. Histone ADP-ribosylation in DNA repair, replication and transcription. Trends Cell Biol 2011; 21:534-42; PMID:21741840; http://dx.doi.org/10.1016/j.tcb.2011.06.001
-
(2011)
Trends Cell Biol
, vol.21
, pp. 534-542
-
-
Messner, S.1
Hottiger, M.O.2
-
48
-
-
84887503435
-
Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein
-
23926104,; PMID
-
Kulkarni A, Oza J, Yao M, Sohail H, Ginjala V, Tomas-Loba A, Horejsi Z, Tan AR, Boulton SJ, Ganesan S. Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein. J Biol Chem 2013; 288:32357-69; PMID:23926104; http://dx.doi.org/10.1074/jbc.M113.459164
-
(2013)
J Biol Chem
, vol.288
, pp. 32357-32369
-
-
Kulkarni, A.1
Oza, J.2
Yao, M.3
Sohail, H.4
Ginjala, V.5
Tomas-Loba, A.6
Horejsi, Z.7
Tan, A.R.8
Boulton, S.J.9
Ganesan, S.10
-
49
-
-
69949184069
-
New functions for an ancient domain
-
19739287,; PMID
-
Kraus WL. New functions for an ancient domain. Nat Struct Mol Biol 2009; 16:904-7; PMID:19739287; http://dx.doi.org/10.1038/nsmb0909-904
-
(2009)
Nat Struct Mol Biol
, vol.16
, pp. 904-907
-
-
Kraus, W.L.1
-
50
-
-
69949133036
-
A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation
-
19680243, et al.,; PMID
-
Timinszky G, Till S, Hassa PO, Hothorn M, Kustatscher G, Nijmeijer B, Colombelli J, Altmeyer M, Stelzer EH, Scheffzek K, et al. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat Struct Mol Biol 2009; 16:923-9; PMID:19680243; http://dx.doi.org/10.1038/nsmb.1664
-
(2009)
Nat Struct Mol Biol
, vol.16
, pp. 923-929
-
-
Timinszky, G.1
Till, S.2
Hassa, P.O.3
Hothorn, M.4
Kustatscher, G.5
Nijmeijer, B.6
Colombelli, J.7
Altmeyer, M.8
Stelzer, E.H.9
Scheffzek, K.10
-
51
-
-
69549083315
-
Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler
-
19666485, et al.,; PMID
-
Gottschalk AJ, Timinszky G, Kong SE, Jin J, Cai Y, Swanson SK, Washburn MP, Florens L, Ladurner AG, Conaway JW, et al. Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc Natl Acad Sci U S A 2009; 106:13770-4; PMID:19666485; http://dx.doi.org/10.1073/pnas.0906920106
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 13770-13774
-
-
Gottschalk, A.J.1
Timinszky, G.2
Kong, S.E.3
Jin, J.4
Cai, Y.5
Swanson, S.K.6
Washburn, M.P.7
Florens, L.8
Ladurner, A.G.9
Conaway, J.W.10
-
52
-
-
69949123856
-
Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1
-
19661379, et al.,; PMID
-
Ahel D, Horejsi Z, Wiechens N, Polo SE, Garcia-Wilson E, Ahel I, Flynn H, Skehel M, West SC, Jackson SP, et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 2009; 325:1240-3; PMID:19661379; http://dx.doi.org/10.1126/science.1177321
-
(2009)
Science
, vol.325
, pp. 1240-1243
-
-
Ahel, D.1
Horejsi, Z.2
Wiechens, N.3
Polo, S.E.4
Garcia-Wilson, E.5
Ahel, I.6
Flynn, H.7
Skehel, M.8
West, S.C.9
Jackson, S.P.10
-
53
-
-
58749112769
-
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
-
18981049,; PMID
-
Gagne JP, Isabelle M, Lo KS, Bourassa S, Hendzel MJ, Dawson VL, Dawson TM, Poirier GG. Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res 2008; 36:6959-76; PMID:18981049; http://dx.doi.org/10.1093/nar/gkn771
-
(2008)
Nucleic Acids Res
, vol.36
, pp. 6959-6976
-
-
Gagne, J.P.1
Isabelle, M.2
Lo, K.S.3
Bourassa, S.4
Hendzel, M.J.5
Dawson, V.L.6
Dawson, T.M.7
Poirier, G.G.8
-
54
-
-
24744447821
-
The role of poly(ADP-ribose) in the DNA damage signaling network
-
15959561,; PMID
-
Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem Cell Biol 2005; 83:354-64; PMID:15959561; http://dx.doi.org/10.1139/o05-038
-
(2005)
Biochem Cell Biol
, vol.83
, pp. 354-364
-
-
Malanga, M.1
Althaus, F.R.2
-
55
-
-
0037462597
-
Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci
-
12543974,; PMID
-
Tulin A, Spradling A. Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci. Science 2003; 299:560-2; PMID:12543974; http://dx.doi.org/10.1126/science.1078764
-
(2003)
Science
, vol.299
, pp. 560-562
-
-
Tulin, A.1
Spradling, A.2
-
56
-
-
2942703171
-
Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure
-
6808510,; PMID
-
Poirier GG, de Murcia G, Jongstra-Bilen J, Niedergang C, Mandel P. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc Natl Acad Sci U S A 1982; 79:3423-7; PMID:6808510; http://dx.doi.org/10.1073/pnas.79.11.3423
-
(1982)
Proc Natl Acad Sci U S A
, vol.79
, pp. 3423-3427
-
-
Poirier, G.G.1
de Murcia, G.2
Jongstra-Bilen, J.3
Niedergang, C.4
Mandel, P.5
-
57
-
-
0019332813
-
ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites
-
6772638,; PMID
-
Ogata N, Ueda K, Kagamiyama H, Hayaishi O. ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites. J Biol Chem 1980; 255:7616-20; PMID:6772638
-
(1980)
J Biol Chem
, vol.255
, pp. 7616-7620
-
-
Ogata, N.1
Ueda, K.2
Kagamiyama, H.3
Hayaishi, O.4
-
58
-
-
33644849513
-
Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase
-
16278211,; PMID
-
Oka S, Kato J, Moss J. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem 2006; 281:705-13; PMID:16278211; http://dx.doi.org/10.1074/jbc.M510290200
-
(2006)
J Biol Chem
, vol.281
, pp. 705-713
-
-
Oka, S.1
Kato, J.2
Moss, J.3
-
59
-
-
2942707644
-
Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments
-
15212953,; PMID
-
Meyer-Ficca ML, Meyer RG, Coyle DL, Jacobson EL, Jacobson MK. Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp Cell Res 2004; 297:521-32; PMID:15212953; http://dx.doi.org/10.1016/j.yexcr.2004.03.050
-
(2004)
Exp Cell Res
, vol.297
, pp. 521-532
-
-
Meyer-Ficca, M.L.1
Meyer, R.G.2
Coyle, D.L.3
Jacobson, E.L.4
Jacobson, M.K.5
-
60
-
-
84877634923
-
Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease
-
23481255, et al.,; PMID
-
Sharifi R, Morra R, Appel CD, Tallis M, Chioza B, Jankevicius G, Simpson MA, Matic I, Ozkan E, Golia B, et al. Deficiency of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease. EMBO J 2013; 32:1225-37; PMID:23481255; http://dx.doi.org/10.1038/emboj.2013.51
-
(2013)
EMBO J
, vol.32
, pp. 1225-1237
-
-
Sharifi, R.1
Morra, R.2
Appel, C.D.3
Tallis, M.4
Chioza, B.5
Jankevicius, G.6
Simpson, M.A.7
Matic, I.8
Ozkan, E.9
Golia, B.10
-
61
-
-
63849115360
-
Parthanatos, a messenger of death
-
19273119,; PMID
-
David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed) 2009; 14:1116-28; PMID:19273119; http://dx.doi.org/10.2741/3297
-
(2009)
Front Biosci (Landmark Ed)
, vol.14
, pp. 1116-1128
-
-
David, K.K.1
Andrabi, S.A.2
Dawson, T.M.3
Dawson, V.L.4
-
62
-
-
84908205819
-
Poly(ADP-ribose): a signaling molecule in different paradigms of cell death
-
24976506,; PMID
-
Aredia F, Scovassi AI. Poly(ADP-ribose): a signaling molecule in different paradigms of cell death. Biochem Pharmacol 2014; 92:157-63; PMID:24976506; http://dx.doi.org/10.1016/j.bcp.2014.06.021
-
(2014)
Biochem Pharmacol
, vol.92
, pp. 157-163
-
-
Aredia, F.1
Scovassi, A.I.2
-
63
-
-
79953840957
-
Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos)
-
21467298,; PMID
-
Wang Y, Kim NS, Haince JF, Kang HC, David KK, Andrabi SA, Poirier GG, Dawson VL, Dawson TM. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal 2011; 4:ra20; PMID:21467298
-
(2011)
Sci Signal
, vol.4
, pp. ra20
-
-
Wang, Y.1
Kim, N.S.2
Haince, J.F.3
Kang, H.C.4
David, K.K.5
Andrabi, S.A.6
Poirier, G.G.7
Dawson, V.L.8
Dawson, T.M.9
-
64
-
-
67649491430
-
Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos)
-
19457082,; PMID
-
Wang Y, Kim NS, Li X, Greer PA, Koehler RC, Dawson VL, Dawson TM. Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos). J Neurochem 2009; 110:687-96; PMID:19457082; http://dx.doi.org/10.1111/j.1471-4159.2009.06167.x
-
(2009)
J Neurochem
, vol.110
, pp. 687-696
-
-
Wang, Y.1
Kim, N.S.2
Li, X.3
Greer, P.A.4
Koehler, R.C.5
Dawson, V.L.6
Dawson, T.M.7
-
65
-
-
0020980976
-
Poly(ADP-ribose) polymerase mediates the suicide response to massive DNA damage: studies in normal and DNA-repair defective cells
-
6317637,; PMID
-
Berger NA, Sims JL, Catino DM, Berger SJ. Poly(ADP-ribose) polymerase mediates the suicide response to massive DNA damage: studies in normal and DNA-repair defective cells. Princess Takamatsu Symp 1983; 13:219-26; PMID:6317637
-
(1983)
Princess Takamatsu Symp
, vol.13
, pp. 219-226
-
-
Berger, N.A.1
Sims, J.L.2
Catino, D.M.3
Berger, S.J.4
-
66
-
-
79958079994
-
Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death
-
21602803, et al.,; PMID
-
Andrabi SA, Kang HC, Haince JF, Lee YI, Zhang J, Chi Z, West AB, Koehler RC, Poirier GG, Dawson TM, et al. Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nat Med 2011; 17:692-9; PMID:21602803; http://dx.doi.org/10.1038/nm.2387
-
(2011)
Nat Med
, vol.17
, pp. 692-699
-
-
Andrabi, S.A.1
Kang, H.C.2
Haince, J.F.3
Lee, Y.I.4
Zhang, J.5
Chi, Z.6
West, A.B.7
Koehler, R.C.8
Poirier, G.G.9
Dawson, T.M.10
-
67
-
-
84975897814
-
Chloroquine and hydroxychloroquine for cancer therapy
-
http://dx.doi.org/
-
Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol 2014; 1:e29911; http://dx.doi.org/10.4161/mco.29911
-
(2014)
Mol Cell Oncol
, vol.1
, pp. e29911
-
-
Manic, G.1
Obrist, F.2
Kroemer, G.3
Vitale, I.4
Galluzzi, L.5
-
68
-
-
85051518561
-
Trial Watch: Proteasomal inhibitors for anticancer therapy
-
2:e974463; http://dx.doi.org/
-
Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol 2014; 2:e974463; http://dx.doi.org/10.4161/23723556.2014.974463
-
(2014)
Mol Cell Oncol
-
-
Obrist, F.1
Manic, G.2
Kroemer, G.3
Vitale, I.4
Galluzzi, L.5
-
69
-
-
0035012606
-
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression
-
11359911,; PMID
-
Tong WM, Hande MP, Lansdorp PM, Wang ZQ. DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression. Mol Cell Biol 2001; 21:4046-54; PMID:11359911; http://dx.doi.org/10.1128/MCB.21.12.4046-4054.2001
-
(2001)
Mol Cell Biol
, vol.21
, pp. 4046-4054
-
-
Tong, W.M.1
Hande, M.P.2
Lansdorp, P.M.3
Wang, Z.Q.4
-
70
-
-
0032102896
-
DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines
-
9592149,; PMID
-
Trucco C, Oliver FJ, de Murcia G, Menissier-de Murcia J. DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res 1998; 26:2644-9; PMID:9592149; http://dx.doi.org/10.1093/nar/26.11.2644
-
(1998)
Nucleic Acids Res
, vol.26
, pp. 2644-2649
-
-
Trucco, C.1
Oliver, F.J.2
de Murcia, G.3
Menissier-de Murcia, J.4
-
71
-
-
77952426818
-
Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice
-
20154718, et al.,; PMID
-
Nicolas L, Martinez C, Baro C, Rodriguez M, Baroja-Mazo A, Sole F, Flores JM, Ampurdanes C, Dantzer F, Martin-Caballero J, et al. Loss of poly(ADP-ribose) polymerase-2 leads to rapid development of spontaneous T-cell lymphomas in p53-deficient mice. Oncogene 2010; 29:2877-83; PMID:20154718; http://dx.doi.org/10.1038/onc.2010.11
-
(2010)
Oncogene
, vol.29
, pp. 2877-2883
-
-
Nicolas, L.1
Martinez, C.2
Baro, C.3
Rodriguez, M.4
Baroja-Mazo, A.5
Sole, F.6
Flores, J.M.7
Ampurdanes, C.8
Dantzer, F.9
Martin-Caballero, J.10
-
72
-
-
0038219534
-
Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse
-
12727891, et al.,; PMID
-
Menissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, Schreiber V, Ame JC, Dierich A, LeMeur M, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003; 22:2255-63; PMID:12727891; http://dx.doi.org/10.1093/emboj/cdg206
-
(2003)
EMBO J
, vol.22
, pp. 2255-2263
-
-
Menissier de Murcia, J.1
Ricoul, M.2
Tartier, L.3
Niedergang, C.4
Huber, A.5
Dantzer, F.6
Schreiber, V.7
Ame, J.C.8
Dierich, A.9
LeMeur, M.10
-
73
-
-
34249948702
-
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice
-
17160013,; PMID
-
Tong WM, Yang YG, Cao WH, Galendo D, Frappart L, Shen Y, Wang ZQ. Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice. Oncogene 2007; 26:3857-67; PMID:17160013; http://dx.doi.org/10.1038/sj.onc.1210156
-
(2007)
Oncogene
, vol.26
, pp. 3857-3867
-
-
Tong, W.M.1
Yang, Y.G.2
Cao, W.H.3
Galendo, D.4
Frappart, L.5
Shen, Y.6
Wang, Z.Q.7
-
74
-
-
0036894745
-
Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation
-
12460917,; PMID
-
Tong WM, Cortes U, Hande MP, Ohgaki H, Cavalli LR, Lansdorp PM, Haddad BR, Wang ZQ. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res 2002; 62:6990-6; PMID:12460917
-
(2002)
Cancer Res
, vol.62
, pp. 6990-6996
-
-
Tong, W.M.1
Cortes, U.2
Hande, M.P.3
Ohgaki, H.4
Cavalli, L.R.5
Lansdorp, P.M.6
Haddad, B.R.7
Wang, Z.Q.8
-
75
-
-
84925270121
-
An update on PARP inhibitors–moving to the adjuvant setting
-
25286972,; PMID
-
Sonnenblick A, de Azambuja E, Azim HA, Jr., Piccart M. An update on PARP inhibitors–moving to the adjuvant setting. Nat Rev Clin Oncol 2015; 12:27-41; PMID:25286972; http://dx.doi.org/10.1038/nrclinonc.2014.163
-
(2015)
Nat Rev Clin Oncol
, vol.12
, pp. 27-41
-
-
Sonnenblick, A.1
de Azambuja, E.2
Azim, H.A.3
Piccart, M.4
-
76
-
-
0030679762
-
Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis
-
9398855,; PMID
-
Morrison C, Smith GC, Stingl L, Jackson SP, Wagner EF, Wang ZQ. Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat Genet 1997; 17:479-82; PMID:9398855; http://dx.doi.org/10.1038/ng1297-479
-
(1997)
Nat Genet
, vol.17
, pp. 479-482
-
-
Morrison, C.1
Smith, G.C.2
Stingl, L.3
Jackson, S.P.4
Wagner, E.F.5
Wang, Z.Q.6
-
77
-
-
77952573915
-
Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice
-
19415146,; PMID
-
Piskunova TS, Yurova MN, Ovsyannikov AI, Semenchenko AV, Zabezhinski MA, Popovich IG, Wang ZQ, Anisimov VN. Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice. Curr Gerontol Geriatr Res 2008; PMID:19415146; http://dx.doi.org/10.1155/2008/754190
-
(2008)
Curr Gerontol Geriatr Res
-
-
Piskunova, T.S.1
Yurova, M.N.2
Ovsyannikov, A.I.3
Semenchenko, A.V.4
Zabezhinski, M.A.5
Popovich, I.G.6
Wang, Z.Q.7
Anisimov, V.N.8
-
78
-
-
84894073889
-
Interaction between PARP-1 and HIF-2alpha in the hypoxic response
-
23455322, et al.,; PMID
-
Gonzalez-Flores A, Aguilar-Quesada R, Siles E, Pozo S, Rodriguez-Lara MI, Lopez-Jimenez L, Lopez-Rodriguez M, Peralta-Leal A, Villar D, Martin-Oliva D, et al. Interaction between PARP-1 and HIF-2alpha in the hypoxic response. Oncogene 2014; 33:891-8; PMID:23455322; http://dx.doi.org/10.1038/onc.2013.9
-
(2014)
Oncogene
, vol.33
, pp. 891-898
-
-
Gonzalez-Flores, A.1
Aguilar-Quesada, R.2
Siles, E.3
Pozo, S.4
Rodriguez-Lara, M.I.5
Lopez-Jimenez, L.6
Lopez-Rodriguez, M.7
Peralta-Leal, A.8
Villar, D.9
Martin-Oliva, D.10
-
79
-
-
80054765289
-
Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells
-
21870269,; PMID
-
Boehler C, Gauthier L, Yelamos J, Noll A, Schreiber V, Dantzer F. Phenotypic characterization of Parp-1 and Parp-2 deficient mice and cells. Methods Mol Biol 2011; 780:313-36; PMID:21870269
-
(2011)
Methods Mol Biol
, vol.780
, pp. 313-336
-
-
Boehler, C.1
Gauthier, L.2
Yelamos, J.3
Noll, A.4
Schreiber, V.5
Dantzer, F.6
-
80
-
-
0035131124
-
Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development
-
11238919,; PMID
-
Menisser-de Murcia J, Mark M, Wendling O, Wynshaw-Boris A, de Murcia G. Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development. Mol Cell Biol 2001; 21:1828-32; PMID:11238919; http://dx.doi.org/10.1128/MCB.21.5.1828-1832.2001
-
(2001)
Mol Cell Biol
, vol.21
, pp. 1828-1832
-
-
Menisser-de Murcia, J.1
Mark, M.2
Wendling, O.3
Wynshaw-Boris, A.4
de Murcia, G.5
-
81
-
-
3242891383
-
PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development
-
15279798,; PMID
-
Huber A, Bai P, de Murcia JM, de Murcia G. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair (Amst) 2004; 3:1103-8; PMID:15279798; http://dx.doi.org/10.1016/j.dnarep.2004.06.002
-
(2004)
DNA Repair (Amst)
, vol.3
, pp. 1103-1108
-
-
Huber, A.1
Bai, P.2
de Murcia, J.M.3
de Murcia, G.4
-
82
-
-
33646113598
-
Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo; [4,5-f]quinoline in mice
-
15955622,; PMID
-
Ogawa K, Masutani M, Kato K, Tang M, Kamada N, Suzuki H, Nakagama H, Sugimura T, Shirai T. Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo; [4,5-f]quinoline in mice. Cancer Lett 2006; 236:32-8; PMID:15955622; http://dx.doi.org/10.1016/j.canlet.2005.04.030
-
(2006)
Cancer Lett
, vol.236
, pp. 32-38
-
-
Ogawa, K.1
Masutani, M.2
Kato, K.3
Tang, M.4
Kamada, N.5
Suzuki, H.6
Nakagama, H.7
Sugimura, T.8
Shirai, T.9
-
83
-
-
34548151570
-
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts
-
16338061,; PMID
-
Gunji A, Uemura A, Tsutsumi M, Nozaki T, Kusuoka O, Omura K, Suzuki H, Nakagama H, Sugimura T, Masutani M. Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts. Cancer Lett 2006; 241:87-92; PMID:16338061; http://dx.doi.org/10.1016/j.canlet.2005.10.003
-
(2006)
Cancer Lett
, vol.241
, pp. 87-92
-
-
Gunji, A.1
Uemura, A.2
Tsutsumi, M.3
Nozaki, T.4
Kusuoka, O.5
Omura, K.6
Suzuki, H.7
Nakagama, H.8
Sugimura, T.9
Masutani, M.10
-
84
-
-
20044369162
-
Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent
-
15608683,; PMID
-
Shibata A, Kamada N, Masumura K, Nohmi T, Kobayashi S, Teraoka H, Nakagama H, Sugimura T, Suzuki H, Masutani M. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. Oncogene 2005; 24:1328-37; PMID:15608683; http://dx.doi.org/10.1038/sj.onc.1208289
-
(2005)
Oncogene
, vol.24
, pp. 1328-1337
-
-
Shibata, A.1
Kamada, N.2
Masumura, K.3
Nohmi, T.4
Kobayashi, S.5
Teraoka, H.6
Nakagama, H.7
Sugimura, T.8
Suzuki, H.9
Masutani, M.10
-
85
-
-
65049083461
-
Role of Parp-1 in suppressing spontaneous deletion mutation in the liver and brain of mice at adolescence and advanced age
-
19428377,; PMID
-
Shibata A, Maeda D, Ogino H, Tsutsumi M, Nohmi T, Nakagama H, Sugimura T, Teraoka H, Masutani M. Role of Parp-1 in suppressing spontaneous deletion mutation in the liver and brain of mice at adolescence and advanced age. Mutat Res 2009; 664:20-7; PMID:19428377; http://dx.doi.org/10.1016/j.mrfmmm.2009.02.001
-
(2009)
Mutat Res
, vol.664
, pp. 20-27
-
-
Shibata, A.1
Maeda, D.2
Ogino, H.3
Tsutsumi, M.4
Nohmi, T.5
Nakagama, H.6
Sugimura, T.7
Teraoka, H.8
Masutani, M.9
-
86
-
-
0033539651
-
Chromosomal aberrations in PARP(−/−) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA
-
10557296,; PMID
-
Simbulan-Rosenthal CM, Haddad BR, Rosenthal DS, Weaver Z, Coleman A, Luo R, Young HM, Wang ZQ, Ried T, Smulson ME. Chromosomal aberrations in PARP(−/−) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA. Proc Natl Acad Sci U S A 1999; 96:13191-6; PMID:10557296; http://dx.doi.org/10.1073/pnas.96.23.13191
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 13191-13196
-
-
Simbulan-Rosenthal, C.M.1
Haddad, B.R.2
Rosenthal, D.S.3
Weaver, Z.4
Coleman, A.5
Luo, R.6
Young, H.M.7
Wang, Z.Q.8
Ried, T.9
Smulson, M.E.10
-
87
-
-
75549091021
-
; [Diethylnitrosamine-induced carcinogenesis in PARP-1(−/−) and PARP-1(+/+) mice]
-
20020658,; PMID
-
Piskunova TS, Zabezhinskii MA, Popovich IG, Tyndyk ML, Iurova MN, Anisimov VN.; [Diethylnitrosamine-induced carcinogenesis in PARP-1(−/−) and PARP-1(+/+) mice]. Vopr Onkol 2009; 55:608-11; PMID:20020658
-
(2009)
Vopr Onkol
, vol.55
, pp. 608-611
-
-
Piskunova, T.S.1
Zabezhinskii, M.A.2
Popovich, I.G.3
Tyndyk, M.L.4
Iurova, M.N.5
Anisimov, V.N.6
-
88
-
-
0035132977
-
Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity
-
11159733,; PMID
-
Tsutsumi M, Masutani M, Nozaki T, Kusuoka O, Tsujiuchi T, Nakagama H, Suzuki H, Konishi Y, Sugimura T. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity. Carcinogenesis 2001; 22:1-3; PMID:11159733; http://dx.doi.org/10.1093/carcin/22.1.1
-
(2001)
Carcinogenesis
, vol.22
, pp. 1-3
-
-
Tsutsumi, M.1
Masutani, M.2
Nozaki, T.3
Kusuoka, O.4
Tsujiuchi, T.5
Nakagama, H.6
Suzuki, H.7
Konishi, Y.8
Sugimura, T.9
-
89
-
-
0038640934
-
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane
-
12824873, et al.,; PMID
-
Nozaki T, Fujihara H, Watanabe M, Tsutsumi M, Nakamoto K, Kusuoka O, Kamada N, Suzuki H, Nakagama H, Sugimura T, et al. Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane. Cancer Sci 2003; 94:497-500; PMID:12824873; http://dx.doi.org/10.1111/j.1349-7006.2003.tb01472.x
-
(2003)
Cancer Sci
, vol.94
, pp. 497-500
-
-
Nozaki, T.1
Fujihara, H.2
Watanabe, M.3
Tsutsumi, M.4
Nakamoto, K.5
Kusuoka, O.6
Kamada, N.7
Suzuki, H.8
Nakagama, H.9
Sugimura, T.10
-
90
-
-
53349153003
-
PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma
-
18660545, Di, et al.,; PMID
-
Tanori M, Mancuso M, Pasquali E, Leonardi S, Rebessi S, Di Majo V, Guilly MN, Giangaspero F, Covelli V, Pazzaglia S, et al. PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma. Carcinogenesis 2008; 29:1911-9; PMID:18660545; http://dx.doi.org/10.1093/carcin/bgn174
-
(2008)
Carcinogenesis
, vol.29
, pp. 1911-1919
-
-
Tanori, M.1
Mancuso, M.2
Pasquali, E.3
Leonardi, S.4
Rebessi, S.5
Majo, V.6
Guilly, M.N.7
Giangaspero, F.8
Covelli, V.9
Pazzaglia, S.10
-
91
-
-
25444468291
-
Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis
-
16204055,; PMID
-
Raval-Fernandes S, Kickhoefer VA, Kitchen C, Rome LH. Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis. Cancer Res 2005; 65:8846-52; PMID:16204055; http://dx.doi.org/10.1158/0008-5472.CAN-05-0770
-
(2005)
Cancer Res
, vol.65
, pp. 8846-8852
-
-
Raval-Fernandes, S.1
Kickhoefer, V.A.2
Kitchen, C.3
Rome, L.H.4
-
92
-
-
78649815064
-
Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis
-
20926829,; PMID
-
Min W, Cortes U, Herceg Z, Tong WM, Wang ZQ. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Carcinogenesis 2010; 31:2058-65; PMID:20926829; http://dx.doi.org/10.1093/carcin/bgq205
-
(2010)
Carcinogenesis
, vol.31
, pp. 2058-2065
-
-
Min, W.1
Cortes, U.2
Herceg, Z.3
Tong, W.M.4
Wang, Z.Q.5
-
93
-
-
18544386364
-
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease
-
15868402,; PMID
-
Masutani M, Nakagama H, Sugimura T. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease. Cell Mol Life Sci 2005; 62:769-83; PMID:15868402; http://dx.doi.org/10.1007/s00018-004-4509-x
-
(2005)
Cell Mol Life Sci
, vol.62
, pp. 769-783
-
-
Masutani, M.1
Nakagama, H.2
Sugimura, T.3
-
94
-
-
4344646721
-
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function
-
15342424,; PMID
-
Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, Hu JJ. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004; 64:6344-8; PMID:15342424; http://dx.doi.org/10.1158/0008-5472.CAN-04-0338
-
(2004)
Cancer Res
, vol.64
, pp. 6344-6348
-
-
Lockett, K.L.1
Hall, M.C.2
Xu, J.3
Zheng, S.L.4
Berwick, M.5
Chuang, S.C.6
Clark, P.E.7
Cramer, S.D.8
Lohman, K.9
Hu, J.J.10
-
95
-
-
3042614143
-
Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma
-
15205355, et al.,; PMID
-
Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, Zhu Y, Miao X, Tan W, Wei Q, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004; 64:4378-84; PMID:15205355; http://dx.doi.org/10.1158/0008-5472.CAN-04-0372
-
(2004)
Cancer Res
, vol.64
, pp. 4378-4384
-
-
Hao, B.1
Wang, H.2
Zhou, K.3
Li, Y.4
Chen, X.5
Zhou, G.6
Zhu, Y.7
Miao, X.8
Tan, W.9
Wei, Q.10
-
96
-
-
13444306156
-
Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer
-
15705867, et al.,; PMID
-
Zhang X, Miao X, Liang G, Hao B, Wang Y, Tan W, Li Y, Guo Y, He F, Wei Q, et al. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005; 65:722-6; PMID:15705867
-
(2005)
Cancer Res
, vol.65
, pp. 722-726
-
-
Zhang, X.1
Miao, X.2
Liang, G.3
Hao, B.4
Wang, Y.5
Tan, W.6
Li, Y.7
Guo, Y.8
He, F.9
Wei, Q.10
-
97
-
-
84862093038
-
PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma
-
22624032,; PMID
-
Ye F, Cheng Q, Hu Y, Zhang J, Chen H. PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma. PLoS One 2012; 7:e37446; PMID:22624032; http://dx.doi.org/10.1371/journal.pone.0037446
-
(2012)
PLoS One
, vol.7
-
-
Ye, F.1
Cheng, Q.2
Hu, Y.3
Zhang, J.4
Chen, H.5
-
98
-
-
84880788171
-
Involvement of PARP-1 Val762Ala polymorphism in the onset of cervical cancer in caucasian women
-
23633189,; PMID
-
Roszak A, Lianeri M, Sowinska A, Jagodzinski PP. Involvement of PARP-1 Val762Ala polymorphism in the onset of cervical cancer in caucasian women. Mol Diagn Ther 2013; 17:239-45; PMID:23633189; http://dx.doi.org/10.1007/s40291-013-0036-5
-
(2013)
Mol Diagn Ther
, vol.17
, pp. 239-245
-
-
Roszak, A.1
Lianeri, M.2
Sowinska, A.3
Jagodzinski, P.P.4
-
99
-
-
84859106641
-
Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis
-
22127734,; PMID
-
Yu H, Ma H, Yin M, Wei Q. Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis. Genet Epidemiol 2012; 36:56-65; PMID:22127734; http://dx.doi.org/10.1002/gepi.20663
-
(2012)
Genet Epidemiol
, vol.36
, pp. 56-65
-
-
Yu, H.1
Ma, H.2
Yin, M.3
Wei, Q.4
-
100
-
-
84901290705
-
PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies
-
24853559,; PMID
-
Qin Q, Lu J, Zhu H, Xu L, Cheng H, Zhan L, Yang X, Zhang C, Sun X. PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies. PLoS One 2014; 9:e98022; PMID:24853559; http://dx.doi.org/10.1371/journal.pone.0098022
-
(2014)
PLoS One
, vol.9
-
-
Qin, Q.1
Lu, J.2
Zhu, H.3
Xu, L.4
Cheng, H.5
Zhan, L.6
Yang, X.7
Zhang, C.8
Sun, X.9
-
101
-
-
0025729413
-
Enhanced poly ADP-ribosylation in human leukemia lymphocytes and ovarian cancers
-
1904797,; PMID
-
Singh N. Enhanced poly ADP-ribosylation in human leukemia lymphocytes and ovarian cancers. Cancer Lett 1991; 58:131-5; PMID:1904797; http://dx.doi.org/10.1016/0304-3835(91)90035-G
-
(1991)
Cancer Lett
, vol.58
, pp. 131-135
-
-
Singh, N.1
-
102
-
-
84904616095
-
-2 and complex chromosomal abnormalities
-
24856976,; PMID
-
-2 and complex chromosomal abnormalities. Hum Pathol 2014; 45:1582-7; PMID:24856976; http://dx.doi.org/10.1016/j.humpath.2013.11.024
-
(2014)
Hum Pathol
, vol.45
, pp. 1582-1587
-
-
Pournazari, P.1
Padmore, R.F.2
Kosari, F.3
Scalia, P.4
Shahbani-Rad, M.T.5
Shariff, S.6
Demetrick, D.J.7
Bosch, M.8
Mansoor, A.9
-
103
-
-
79952852791
-
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types
-
21779467,; PMID
-
Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM. Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010; 1:812-21; PMID:21779467; http://dx.doi.org/10.1177/1947601910383418
-
(2010)
Genes Cancer
, vol.1
, pp. 812-821
-
-
Ossovskaya, V.1
Koo, I.C.2
Kaldjian, E.P.3
Alvares, C.4
Sherman, B.M.5
-
104
-
-
84885604912
-
Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome
-
23736962,; PMID
-
Bieche I, Pennaneach V, Driouch K, Vacher S, Zaremba T, Susini A, Lidereau R, Hall J. Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome. Int J Cancer 2013; 133:2791-800; PMID:23736962
-
(2013)
Int J Cancer
, vol.133
, pp. 2791-2800
-
-
Bieche, I.1
Pennaneach, V.2
Driouch, K.3
Vacher, S.4
Zaremba, T.5
Susini, A.6
Lidereau, R.7
Hall, J.8
-
105
-
-
84858957528
-
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
-
21908496, et al.,; PMID
-
Rojo F, Garcia-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramirez-Merino N, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012; 23:1156-64; PMID:21908496; http://dx.doi.org/10.1093/annonc/mdr361
-
(2012)
Ann Oncol
, vol.23
, pp. 1156-1164
-
-
Rojo, F.1
Garcia-Parra, J.2
Zazo, S.3
Tusquets, I.4
Ferrer-Lozano, J.5
Menendez, S.6
Eroles, P.7
Chamizo, C.8
Servitja, S.9
Ramirez-Merino, N.10
-
106
-
-
79955738892
-
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
-
21409392,; PMID
-
Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011; 127:861-9; PMID:21409392; http://dx.doi.org/10.1007/s10549-011-1441-2
-
(2011)
Breast Cancer Res Treat
, vol.127
, pp. 861-869
-
-
Domagala, P.1
Huzarski, T.2
Lubinski, J.3
Gugala, K.4
Domagala, W.5
-
107
-
-
84868479267
-
Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV)
-
22454210,; PMID
-
Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, Soares EG. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathol Oncol Res 2012; 18:929-37; PMID:22454210; http://dx.doi.org/10.1007/s12253-012-9523-y
-
(2012)
Pathol Oncol Res
, vol.18
, pp. 929-937
-
-
Hassumi-Fukasawa, M.K.1
Miranda-Camargo, F.A.2
Zanetti, B.R.3
Galano, D.F.4
Ribeiro-Silva, A.5
Soares, E.G.6
-
108
-
-
84878230384
-
Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma
-
23652727,; PMID
-
Tang Y, Wang YL, Yang L, Xu JX, Xiong W, Xiao M, Li M. Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma. Int J Mol Med 2013; 32:130-6; PMID:23652727
-
(2013)
Int J Mol Med
, vol.32
, pp. 130-136
-
-
Tang, Y.1
Wang, Y.L.2
Yang, L.3
Xu, J.X.4
Xiong, W.5
Xiao, M.6
Li, M.7
-
109
-
-
16844378949
-
Changes in NAD/ADP-ribose metabolism in rectal cancer
-
15761615,; PMID
-
Yalcintepe L, Turker-Sener L, Sener A, Yetkin G, Tiryaki D, Bermek E. Changes in NAD/ADP-ribose metabolism in rectal cancer. Braz J Med Biol Res 2005; 38:361-5; PMID:15761615; http://dx.doi.org/10.1590/S0100-879X2005000300006
-
(2005)
Braz J Med Biol Res
, vol.38
, pp. 361-365
-
-
Yalcintepe, L.1
Turker-Sener, L.2
Sener, A.3
Yetkin, G.4
Tiryaki, D.5
Bermek, E.6
-
110
-
-
33748105074
-
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis
-
16809031,; PMID
-
Nosho K, Yamamoto H, Mikami M, Taniguchi H, Takahashi T, Adachi Y, Imamura A, Imai K, Shinomura Y. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer 2006; 42:2374-81; PMID:16809031; http://dx.doi.org/10.1016/j.ejca.2006.01.061
-
(2006)
Eur J Cancer
, vol.42
, pp. 2374-2381
-
-
Nosho, K.1
Yamamoto, H.2
Mikami, M.3
Taniguchi, H.4
Takahashi, T.5
Adachi, Y.6
Imamura, A.7
Imai, K.8
Shinomura, Y.9
-
111
-
-
33847011050
-
Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate β-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling
-
17283121,; PMID
-
Idogawa M, Masutani M, Shitashige M, Honda K, Tokino T, Shinomura Y, Imai K, Hirohashi S, Yamada T. Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate β-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res 2007; 67:911-8; PMID:17283121; http://dx.doi.org/10.1158/0008-5472.CAN-06-2360
-
(2007)
Cancer Res
, vol.67
, pp. 911-918
-
-
Idogawa, M.1
Masutani, M.2
Shitashige, M.3
Honda, K.4
Tokino, T.5
Shinomura, Y.6
Imai, K.7
Hirohashi, S.8
Yamada, T.9
-
112
-
-
20444503830
-
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/β-catenin complex
-
15940627,; PMID
-
Idogawa M, Yamada T, Honda K, Sato S, Imai K, Hirohashi S. Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/β-catenin complex. Gastroenterology 2005; 128:1919-36; PMID:15940627; http://dx.doi.org/10.1053/j.gastro.2005.03.007
-
(2005)
Gastroenterology
, vol.128
, pp. 1919-1936
-
-
Idogawa, M.1
Yamada, T.2
Honda, K.3
Sato, S.4
Imai, K.5
Hirohashi, S.6
-
113
-
-
79551639516
-
PARP-1 activity in normal and cancerous human endometrium and its relationship with quantity of abasic sites (AP)
-
21469519,; PMID
-
Postawski K, Monist M, Keith G. PARP-1 activity in normal and cancerous human endometrium and its relationship with quantity of abasic sites (AP). Ginekol Pol 2011; 82:16-21; PMID:21469519
-
(2011)
Ginekol Pol
, vol.82
, pp. 16-21
-
-
Postawski, K.1
Monist, M.2
Keith, G.3
-
114
-
-
0034074057
-
Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma
-
10847440,; PMID
-
Nomura F, Yaguchi M, Togawa A, Miyazaki M, Isobe K, Miyake M, Noda M, Nakai T. Enhancement of poly-adenosine diphosphate-ribosylation in human hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15:529-35; PMID:10847440; http://dx.doi.org/10.1046/j.1440-1746.2000.02193.x
-
(2000)
J Gastroenterol Hepatol
, vol.15
, pp. 529-535
-
-
Nomura, F.1
Yaguchi, M.2
Togawa, A.3
Miyazaki, M.4
Isobe, K.5
Miyake, M.6
Noda, M.7
Nakai, T.8
-
115
-
-
84866324536
-
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1
-
22961666, et al.,; PMID
-
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2:798-811; PMID:22961666; http://dx.doi.org/10.1158/2159-8290.CD-12-0112
-
(2012)
Cancer Discov
, vol.2
, pp. 798-811
-
-
Byers, L.A.1
Wang, J.2
Nilsson, M.B.3
Fujimoto, J.4
Saintigny, P.5
Yordy, J.6
Giri, U.7
Peyton, M.8
Fan, Y.H.9
Diao, L.10
-
116
-
-
34748915801
-
Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome
-
17413981,; PMID
-
Brustmann H. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. Int J Gynecol Pathol 2007; 26:147-53; PMID:17413981; http://dx.doi.org/10.1097/pgp.0b013e3180555999
-
(2007)
Int J Gynecol Pathol
, vol.26
, pp. 147-153
-
-
Brustmann, H.1
-
117
-
-
84880333946
-
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival
-
23574784,; PMID
-
Gan A, Green AR, Nolan CC, Martin S, Deen S. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum Pathol 2013; 44:1638-47; PMID:23574784; http://dx.doi.org/10.1016/j.humpath.2013.01.015
-
(2013)
Hum Pathol
, vol.44
, pp. 1638-1647
-
-
Gan, A.1
Green, A.R.2
Nolan, C.C.3
Martin, S.4
Deen, S.5
-
118
-
-
84874212575
-
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer
-
23442605,; PMID
-
Bi FF, Li D, Yang Q. Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer. BMC Cancer 2013; 13:90; PMID:23442605; http://dx.doi.org/10.1186/1471-2407-13-90
-
(2013)
BMC Cancer
, vol.13
, pp. 90
-
-
Bi, F.F.1
Li, D.2
Yang, Q.3
-
119
-
-
84903525442
-
Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients
-
24436031,; PMID
-
Wu W, Zhu H, Liang Y, Kong Z, Duan X, Li S, Zhao Z, Yang D, Zeng G. Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients. Int Urol Nephrol 2014; 46:1345-9; PMID:24436031; http://dx.doi.org/10.1007/s11255-014-0642-0
-
(2014)
Int Urol Nephrol
, vol.46
, pp. 1345-1349
-
-
Wu, W.1
Zhu, H.2
Liang, Y.3
Kong, Z.4
Duan, X.5
Li, S.6
Zhao, Z.7
Yang, D.8
Zeng, G.9
-
120
-
-
84892641981
-
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue
-
23807292,; PMID
-
Salemi M, Galia A, Fraggetta F, La Corte C, Pepe P, La Vignera S, Improta G, Bosco P, Calogero AE. Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue. Eur J Histochem 2013; 57:e13; PMID:23807292; http://dx.doi.org/10.4081/ejh.2013.e13
-
(2013)
Eur J Histochem
, vol.57
, pp. e13
-
-
Salemi, M.1
Galia, A.2
Fraggetta, F.3
La Corte, C.4
Pepe, P.5
La Vignera, S.6
Improta, G.7
Bosco, P.8
Calogero, A.E.9
-
121
-
-
0037900683
-
Intrinsic presence of poly (ADP-ribose) is significantly increased in malignant prostate compared to benign prostate cell lines
-
12820412,; PMID
-
McNealy T, Frey M, Trojan L, Knoll T, Alken P, Michel MS. Intrinsic presence of poly (ADP-ribose) is significantly increased in malignant prostate compared to benign prostate cell lines. Anticancer Res 2003; 23:1473-8; PMID:12820412
-
(2003)
Anticancer Res
, vol.23
, pp. 1473-1478
-
-
McNealy, T.1
Frey, M.2
Trojan, L.3
Knoll, T.4
Alken, P.5
Michel, M.S.6
-
122
-
-
23444443380
-
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region
-
16084940, et al.,; PMID
-
Staibano S, Pepe S, Lo Muzio L, Somma P, Mascolo M, Argenziano G, Scalvenzi M, Salvatore G, Fabbrocini G, Molea G, et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005; 36:724-31; PMID:16084940; http://dx.doi.org/10.1016/j.humpath.2005.04.017
-
(2005)
Hum Pathol
, vol.36
, pp. 724-731
-
-
Staibano, S.1
Pepe, S.2
Lo Muzio, L.3
Somma, P.4
Mascolo, M.5
Argenziano, G.6
Scalvenzi, M.7
Salvatore, G.8
Fabbrocini, G.9
Molea, G.10
-
123
-
-
44449115048
-
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity
-
18440222, et al.,; PMID
-
Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, Shah GM, Zhang J, Navarra P, Nocentini G, et al. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur J Cancer 2008; 44:1302-14; PMID:18440222; http://dx.doi.org/10.1016/j.ejca.2008.03.019
-
(2008)
Eur J Cancer
, vol.44
, pp. 1302-1314
-
-
Tentori, L.1
Muzi, A.2
Dorio, A.S.3
Bultrini, S.4
Mazzon, E.5
Lacal, P.M.6
Shah, G.M.7
Zhang, J.8
Navarra, P.9
Nocentini, G.10
-
124
-
-
0036582736
-
Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells
-
11956622,; PMID
-
Newman RE, Soldatenkov VA, Dritschilo A, Notario V. Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells. Oncol Rep 2002; 9:529-32; PMID:11956622
-
(2002)
Oncol Rep
, vol.9
, pp. 529-532
-
-
Newman, R.E.1
Soldatenkov, V.A.2
Dritschilo, A.3
Notario, V.4
-
125
-
-
0025058865
-
Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells
-
2104538,; PMID
-
Prasad SC, Thraves PJ, Bhatia KG, Smulson ME, Dritschilo A. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res 1990; 50:38-43; PMID:2104538
-
(1990)
Cancer Res
, vol.50
, pp. 38-43
-
-
Prasad, S.C.1
Thraves, P.J.2
Bhatia, K.G.3
Smulson, M.E.4
Dritschilo, A.5
-
126
-
-
84864859391
-
PARP-1 protein expression in glioblastoma multiforme
-
22472897,; PMID
-
Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, Bosco P, Castiglione R, Salemi M. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem 2012; 56:e9; PMID:22472897; http://dx.doi.org/10.4081/ejh.2012.e9
-
(2012)
Eur J Histochem
, vol.56
, pp. e9
-
-
Galia, A.1
Calogero, A.E.2
Condorelli, R.3
Fraggetta, F.4
La Corte, A.5
Ridolfo, F.6
Bosco, P.7
Castiglione, R.8
Salemi, M.9
-
127
-
-
0034524833
-
Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model
-
11123719,; PMID
-
Wharton SB, McNelis U, Bell HS, Whittle IR. Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol Appl Neurobiol 2000; 26:528-35; PMID:11123719; http://dx.doi.org/10.1046/j.0305-1846.2000.00288.x
-
(2000)
Neuropathol Appl Neurobiol
, vol.26
, pp. 528-535
-
-
Wharton, S.B.1
McNelis, U.2
Bell, H.S.3
Whittle, I.R.4
-
128
-
-
84903613949
-
Poly(ADP-ribose) polymerase-1 (PARP1) and p53 labelling index correlates with tumour grade in meningiomas
-
25118896,; PMID
-
Csonka T, Murnyak B, Szepesi R, Kurucz A, Klekner A, Hortobagyi T. Poly(ADP-ribose) polymerase-1 (PARP1) and p53 labelling index correlates with tumour grade in meningiomas. Folia Neuropathol 2014; 52:111-20; PMID:25118896; http://dx.doi.org/10.5114/fn.2014.43782
-
(2014)
Folia Neuropathol
, vol.52
, pp. 111-120
-
-
Csonka, T.1
Murnyak, B.2
Szepesi, R.3
Kurucz, A.4
Klekner, A.5
Hortobagyi, T.6
-
129
-
-
0037051674
-
Reduced poly(ADP-ribosyl)ation in lymphocytes of laryngeal cancer patients: results of a case-control study
-
11920651,; PMID
-
Rajaee-Behbahani N, Schmezer P, Ramroth H, Burkle A, Bartsch H, Dietz A, Becher H. Reduced poly(ADP-ribosyl)ation in lymphocytes of laryngeal cancer patients: results of a case-control study. Int J Cancer 2002; 98:780-4; PMID:11920651; http://dx.doi.org/10.1002/ijc.10234
-
(2002)
Int J Cancer
, vol.98
, pp. 780-784
-
-
Rajaee-Behbahani, N.1
Schmezer, P.2
Ramroth, H.3
Burkle, A.4
Bartsch, H.5
Dietz, A.6
Becher, H.7
-
130
-
-
79957940705
-
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
-
21519019, et al.,; PMID
-
von Minckwitz G, Muller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, et al. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7; PMID:21519019; http://dx.doi.org/10.1200/JCO.2010.31.9079
-
(2011)
J Clin Oncol
, vol.29
, pp. 2150-2157
-
-
von Minckwitz, G.1
Muller, B.M.2
Loibl, S.3
Budczies, J.4
Hanusch, C.5
Darb-Esfahani, S.6
Hilfrich, J.7
Weiss, E.8
Huober, J.9
Blohmer, J.U.10
-
131
-
-
0024448020
-
Poly(ADP-ribose) polymerase inhibits DNA synthesis initiation in the absence of NAD
-
2506850,; PMID
-
Nobori T, Yamanaka H, Carson DA. Poly(ADP-ribose) polymerase inhibits DNA synthesis initiation in the absence of NAD. Biochem Biophys Res Commun 1989; 163:1113-8; PMID:2506850; http://dx.doi.org/10.1016/0006-291X(89)92336-X
-
(1989)
Biochem Biophys Res Commun
, vol.163
, pp. 1113-1118
-
-
Nobori, T.1
Yamanaka, H.2
Carson, D.A.3
-
132
-
-
54549103449
-
-; [3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1
-
18800822, et al. Four,; PMID
-
Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, et al. Four-; [3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51:6581-91; PMID:18800822; http://dx.doi.org/10.1021/jm8001263
-
(2008)
J Med Chem
, vol.51
, pp. 6581-6591
-
-
Menear, K.A.1
Adcock, C.2
Boulter, R.3
Cockcroft, X.L.4
Copsey, L.5
Cranston, A.6
Dillon, K.J.7
Drzewiecki, J.8
Garman, S.9
Gomez, S.10
-
133
-
-
34147182310
-
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
-
17363489, et al.,; PMID
-
Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, Maegley KA, Newell DR, Skalitzky D, Wang LZ, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 2007; 6:945-56; PMID:17363489; http://dx.doi.org/10.1158/1535-7163.MCT-06-0552
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 945-956
-
-
Thomas, H.D.1
Calabrese, C.R.2
Batey, M.A.3
Canan, S.4
Hostomsky, Z.5
Kyle, S.6
Maegley, K.A.7
Newell, D.R.8
Skalitzky, D.9
Wang, L.Z.10
-
134
-
-
34249006299
-
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
-
17473206, et al.,; PMID
-
Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13:2728-37; PMID:17473206; http://dx.doi.org/10.1158/1078-0432.CCR-06-3039
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2728-2737
-
-
Donawho, C.K.1
Luo, Y.2
Luo, Y.3
Penning, T.D.4
Bauch, J.L.5
Bouska, J.J.6
Bontcheva-Diaz, V.D.7
Cox, B.F.8
DeWeese, T.L.9
Dillehay, L.E.10
-
135
-
-
70949086814
-
Discovery of 2-{4-; [(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors
-
19873981, et al.,; PMID
-
Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, et al. Discovery of 2-{4-; [(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 2009; 52:7170-85; PMID:19873981; http://dx.doi.org/10.1021/jm901188v
-
(2009)
J Med Chem
, vol.52
, pp. 7170-7185
-
-
Jones, P.1
Altamura, S.2
Boueres, J.3
Ferrigno, F.4
Fonsi, M.5
Giomini, C.6
Lamartina, S.7
Monteagudo, E.8
Ontoria, J.M.9
Orsale, M.V.10
-
136
-
-
84868208375
-
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
-
22678161,; PMID
-
Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012; 134:649-59; PMID:22678161; http://dx.doi.org/10.1007/s10549-012-2106-5
-
(2012)
Breast Cancer Res Treat
, vol.134
, pp. 649-659
-
-
Chuang, H.C.1
Kapuriya, N.2
Kulp, S.K.3
Chen, C.S.4
Shapiro, C.L.5
-
137
-
-
84858198901
-
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro
-
22291137,; PMID
-
Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 2012; 18:1655-62; PMID:22291137; http://dx.doi.org/10.1158/1078-0432.CCR-11-2890
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1655-1662
-
-
Patel, A.G.1
De Lorenzo, S.B.2
Flatten, K.S.3
Poirier, G.G.4
Kaufmann, S.H.5
-
138
-
-
0029089917
-
Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture
-
7669074,; PMID
-
Mendeleyev J, Kirsten E, Hakam A, Buki KG, Kun E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol 1995; 50:705-14; PMID:7669074; http://dx.doi.org/10.1016/0006-2952(95)00189-7
-
(1995)
Biochem Pharmacol
, vol.50
, pp. 705-714
-
-
Mendeleyev, J.1
Kirsten, E.2
Hakam, A.3
Buki, K.G.4
Kun, E.5
-
139
-
-
34548072788
-
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity
-
17699724, et al.,; PMID
-
Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, Ator M, Husten J, Deibold J, Hudkins R, et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 2007; 6:2290-302; PMID:17699724; http://dx.doi.org/10.1158/1535-7163.MCT-07-0062
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 2290-2302
-
-
Miknyoczki, S.1
Chang, H.2
Grobelny, J.3
Pritchard, S.4
Worrell, C.5
McGann, N.6
Ator, M.7
Husten, J.8
Deibold, J.9
Hudkins, R.10
-
140
-
-
59549097382
-
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016
-
19147766, et al.,; PMID
-
Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, et al. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009; 15:607-12; PMID:19147766; http://dx.doi.org/10.1158/1078-0432.CCR-08-2079
-
(2009)
Clin Cancer Res
, vol.15
, pp. 607-612
-
-
Russo, A.L.1
Kwon, H.C.2
Burgan, W.E.3
Carter, D.4
Beam, K.5
Weizheng, X.6
Zhang, J.7
Slusher, B.S.8
Chakravarti, A.9
Tofilon, P.J.10
-
141
-
-
1242271229
-
Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase
-
15036647,; PMID
-
Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 2004; 205:155-60; PMID:15036647; http://dx.doi.org/10.1016/j.canlet.2003.10.029
-
(2004)
Cancer Lett
, vol.205
, pp. 155-160
-
-
Brock, W.A.1
Milas, L.2
Bergh, S.3
Lo, R.4
Szabo, C.5
Mason, K.A.6
-
142
-
-
84904978889
-
Predictive biomarkers for cancer therapy with PARP inhibitors
-
24037533,; PMID
-
Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene 2014; 33:3894-907; PMID:24037533; http://dx.doi.org/10.1038/onc.2013.352
-
(2014)
Oncogene
, vol.33
, pp. 3894-3907
-
-
Michels, J.1
Vitale, I.2
Saparbaev, M.3
Castedo, M.4
Kroemer, G.5
-
143
-
-
84908210107
-
PARP and other prospective targets for poisoning cancer cell metabolism
-
25199458,; PMID
-
Michels J, Obrist F, Castedo M, Vitale I, Kroemer G. PARP and other prospective targets for poisoning cancer cell metabolism. Biochem Pharmacol 2014; 92:164-71; PMID:25199458; http://dx.doi.org/10.1016/j.bcp.2014.08.026
-
(2014)
Biochem Pharmacol
, vol.92
, pp. 164-171
-
-
Michels, J.1
Obrist, F.2
Castedo, M.3
Vitale, I.4
Kroemer, G.5
-
144
-
-
84886717487
-
Therapeutic applications of PARP inhibitors: anticancer therapy and beyond
-
23370117,; PMID
-
Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013; 34:1217-56; PMID:23370117; http://dx.doi.org/10.1016/j.mam.2013.01.006
-
(2013)
Mol Aspects Med
, vol.34
, pp. 1217-1256
-
-
Curtin, N.J.1
Szabo, C.2
-
145
-
-
84857939963
-
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
-
22343925, et al.,; PMID
-
Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, Pol E, Frostell A, Ekblad T, Oncu D, et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 2012; 30:283-8; PMID:22343925; http://dx.doi.org/10.1038/nbt.2121
-
(2012)
Nat Biotechnol
, vol.30
, pp. 283-288
-
-
Wahlberg, E.1
Karlberg, T.2
Kouznetsova, E.3
Markova, N.4
Macchiarulo, A.5
Thorsell, A.G.6
Pol, E.7
Frostell, A.8
Ekblad, T.9
Oncu, D.10
-
146
-
-
84857936584
-
Advances in using PARP inhibitors to treat cancer
-
22401667,; PMID
-
Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH. Advances in using PARP inhibitors to treat cancer. BMC Med 2012; 10:25; PMID:22401667; http://dx.doi.org/10.1186/1741-7015-10-25
-
(2012)
BMC Med
, vol.10
, pp. 25
-
-
Kummar, S.1
Chen, A.2
Parchment, R.E.3
Kinders, R.J.4
Ji, J.5
Tomaszewski, J.E.6
Doroshow, J.H.7
-
147
-
-
79960703030
-
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality
-
21424107,; PMID
-
Leung M, Rosen D, Fields S, Cesano A, Budman DR. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 2011; 17:854-62; PMID:21424107; http://dx.doi.org/10.2119/molmed.2010.00240
-
(2011)
Mol Med
, vol.17
, pp. 854-862
-
-
Leung, M.1
Rosen, D.2
Fields, S.3
Cesano, A.4
Budman, D.R.5
-
148
-
-
35748970514
-
PARP inhibitor development for systemic cancer targeting
-
17896912,; PMID
-
Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007; 7:515-23; PMID:17896912; http://dx.doi.org/10.2174/187152007781668715
-
(2007)
Anticancer Agents Med Chem
, vol.7
, pp. 515-523
-
-
Zaremba, T.1
Curtin, N.J.2
-
149
-
-
33947380240
-
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology
-
17332279,; PMID
-
Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13:1383-8; PMID:17332279; http://dx.doi.org/10.1158/1078-0432.CCR-06-2260
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1383-1388
-
-
Ratnam, K.1
Low, J.A.2
-
150
-
-
84872625067
-
Genetics of natural populations. Xiii. recombination and variability in populations of drosophila pseudoobscura
-
17247197,; PMID
-
Dobzhansky T. Genetics of natural populations. Xiii. recombination and variability in populations of drosophila pseudoobscura. Genetics 1946; 31:269-90; PMID:17247197
-
(1946)
Genetics
, vol.31
, pp. 269-290
-
-
Dobzhansky, T.1
-
151
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
15829967, et al.,; PMID
-
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
Tutt, A.N.4
Johnson, D.A.5
Richardson, T.B.6
Santarosa, M.7
Dillon, K.J.8
Hickson, I.9
Knights, C.10
-
152
-
-
17244375049
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
-
15829966,; PMID
-
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; http://dx.doi.org/10.1038/nature03443
-
(2005)
Nature
, vol.434
, pp. 913-917
-
-
Bryant, H.E.1
Schultz, N.2
Thomas, H.D.3
Parker, K.M.4
Flower, D.5
Lopez, E.6
Kyle, S.7
Meuth, M.8
Curtin, N.J.9
Helleday, T.10
-
153
-
-
84897012760
-
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
-
24225019,; PMID
-
Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 2014; 25:32-40; PMID:24225019; http://dx.doi.org/10.1093/annonc/mdt384
-
(2014)
Ann Oncol
, vol.25
, pp. 32-40
-
-
Lee, J.M.1
Ledermann, J.A.2
Kohn, E.C.3
-
154
-
-
4944229642
-
Hallmarks of ‘BRCAness’ in sporadic cancers
-
15510162,; PMID
-
Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 2004; 4:814-9; PMID:15510162; http://dx.doi.org/10.1038/nrc1457
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 814-819
-
-
Turner, N.1
Tutt, A.2
Ashworth, A.3
-
155
-
-
33748065304
-
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
-
16912188, et al.,; PMID
-
McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66:8109-15; PMID:16912188; http://dx.doi.org/10.1158/0008-5472.CAN-06-0140
-
(2006)
Cancer Res
, vol.66
, pp. 8109-8115
-
-
McCabe, N.1
Turner, N.C.2
Lord, C.J.3
Kluzek, K.4
Bialkowska, A.5
Swift, S.6
Giavara, S.7
O'Connor, M.J.8
Tutt, A.N.9
Zdzienicka, M.Z.10
-
156
-
-
76649091939
-
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors
-
20124459,; PMID
-
Williamson CT, Muzik H, Turhan AG, Zamo A, O'Connor MJ, Bebb DG, Lees-Miller SP. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010; 9:347-57; PMID:20124459; http://dx.doi.org/10.1158/1535-7163.MCT-09-0872
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 347-357
-
-
Williamson, C.T.1
Muzik, H.2
Turhan, A.G.3
Zamo, A.4
O'Connor, M.J.5
Bebb, D.G.6
Lees-Miller, S.P.7
-
157
-
-
84861907790
-
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
-
22416035, et al.,; PMID
-
Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 2012; 4:515-27; PMID:22416035; http://dx.doi.org/10.1002/emmm.201200229
-
(2012)
EMBO Mol Med
, vol.4
, pp. 515-527
-
-
Williamson, C.T.1
Kubota, E.2
Hamill, J.D.3
Klimowicz, A.4
Ye, R.5
Muzik, H.6
Dean, M.7
Tu, L.8
Gilley, D.9
Magliocco, A.M.10
-
158
-
-
84866854042
-
Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination
-
22833573,; PMID
-
Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination. Mol Pharmacol 2012; 82:767-76; PMID:22833573; http://dx.doi.org/10.1124/mol.112.080614
-
(2012)
Mol Pharmacol
, vol.82
, pp. 767-776
-
-
Huehls, A.M.1
Wagner, J.M.2
Huntoon, C.J.3
Karnitz, L.M.4
-
159
-
-
78649321855
-
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
-
20739657, et al.,; PMID
-
Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010; 116:4578-87; PMID:20739657; http://dx.doi.org/10.1182/blood-2010-01-265769
-
(2010)
Blood
, vol.116
, pp. 4578-4587
-
-
Weston, V.J.1
Oldreive, C.E.2
Skowronska, A.3
Oscier, D.G.4
Pratt, G.5
Dyer, M.J.6
Smith, G.7
Powell, J.E.8
Rudzki, Z.9
Kearns, P.10
-
160
-
-
84887792084
-
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
-
24252502,; PMID
-
Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barila D, Soddu S. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res 2013; 32:95; PMID:24252502; http://dx.doi.org/10.1186/1756-9966-32-95
-
(2013)
J Exp Clin Cancer Res
, vol.32
, pp. 95
-
-
Gilardini Montani, M.S.1
Prodosmo, A.2
Stagni, V.3
Merli, D.4
Monteonofrio, L.5
Gatti, V.6
Gentileschi, M.P.7
Barila, D.8
Soddu, S.9
-
161
-
-
84879091192
-
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status
-
23548269,; PMID
-
Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res 2013; 73:3683-91; PMID:23548269; http://dx.doi.org/10.1158/0008-5472.CAN-13-0110
-
(2013)
Cancer Res
, vol.73
, pp. 3683-3691
-
-
Huntoon, C.J.1
Flatten, K.S.2
Wahner Hendrickson, A.E.3
Huehls, A.M.4
Sutor, S.L.5
Kaufmann, S.H.6
Karnitz, L.M.7
-
162
-
-
34347391035
-
Utilizing RNA interference to enhance cancer drug discovery
-
17599085,; PMID
-
Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007; 6:556-68; PMID:17599085; http://dx.doi.org/10.1038/nrd2355
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 556-568
-
-
Iorns, E.1
Lord, C.J.2
Turner, N.3
Ashworth, A.4
-
163
-
-
0038075462
-
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors
-
12692539,; PMID
-
Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9:568-74; PMID:12692539; http://dx.doi.org/10.1038/nm852
-
(2003)
Nat Med
, vol.9
, pp. 568-574
-
-
Taniguchi, T.1
Tischkowitz, M.2
Ameziane, N.3
Hodgson, S.V.4
Mathew, C.G.5
Joenje, H.6
Mok, S.C.7
D'Andrea, A.D.8
-
164
-
-
33746491583
-
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles
-
16832357, et al.,; PMID
-
Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake H, Barfoot R, Spanova K, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38:873-5; PMID:16832357; http://dx.doi.org/10.1038/ng1837
-
(2006)
Nat Genet
, vol.38
, pp. 873-875
-
-
Renwick, A.1
Thompson, D.2
Seal, S.3
Kelly, P.4
Chagtai, T.5
Ahmed, M.6
North, B.7
Jayatilake, H.8
Barfoot, R.9
Spanova, K.10
-
165
-
-
0034946243
-
Ataxia telangiectasia gene mutations in leukaemia and lymphoma
-
11429421,; PMID
-
Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 2001; 54:512-6; PMID:11429421; http://dx.doi.org/10.1136/jcp.54.7.512
-
(2001)
J Clin Pathol
, vol.54
, pp. 512-516
-
-
Boultwood, J.1
-
166
-
-
33749039966
-
The CHEK2 gene and inherited breast cancer susceptibility
-
16998506,; PMID
-
Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006; 25:5912-9; PMID:16998506; http://dx.doi.org/10.1038/sj.onc.1209877
-
(2006)
Oncogene
, vol.25
, pp. 5912-5919
-
-
Nevanlinna, H.1
Bartek, J.2
-
167
-
-
77149157867
-
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
-
20049735,; PMID
-
Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009; 1:315-22; PMID:20049735; http://dx.doi.org/10.1002/emmm.200900041
-
(2009)
EMBO Mol Med
, vol.1
, pp. 315-322
-
-
Mendes-Pereira, A.M.1
Martin, S.A.2
Brough, R.3
McCarthy, A.4
Taylor, J.R.5
Kim, J.S.6
Waldman, T.7
Lord, C.J.8
Ashworth, A.9
-
168
-
-
77958049428
-
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors
-
20944090, et al.,; PMID
-
Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010; 2:53ra75; PMID:20944090; http://dx.doi.org/10.1126/scitranslmed.3001538
-
(2010)
Sci Transl Med
, vol.2
, pp. 53ra75
-
-
Dedes, K.J.1
Wetterskog, D.2
Mendes-Pereira, A.M.3
Natrajan, R.4
Lambros, M.B.5
Geyer, F.C.6
Vatcheva, R.7
Savage, K.8
Mackay, A.9
Lord, C.J.10
-
169
-
-
77954358148
-
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors
-
20530668,; PMID
-
McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N, Bachoo RM, Burma S. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010; 70:5457-64; PMID:20530668; http://dx.doi.org/10.1158/0008-5472.CAN-09-4295
-
(2010)
Cancer Res
, vol.70
, pp. 5457-5464
-
-
McEllin, B.1
Camacho, C.V.2
Mukherjee, B.3
Hahm, B.4
Tomimatsu, N.5
Bachoo, R.M.6
Burma, S.7
-
170
-
-
84874411631
-
Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells
-
23239809,; PMID
-
Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, Kiura K. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2013; 11:140-8; PMID:23239809; http://dx.doi.org/10.1158/1541-7786.MCR-12-0401
-
(2013)
Mol Cancer Res
, vol.11
, pp. 140-148
-
-
Minami, D.1
Takigawa, N.2
Takeda, H.3
Takata, M.4
Ochi, N.5
Ichihara, E.6
Hisamoto, A.7
Hotta, K.8
Tanimoto, M.9
Kiura, K.10
-
171
-
-
84875683838
-
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells
-
23565244,; PMID
-
Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, Klein EA, Almasan A. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One 2013; 8:e60408; PMID:23565244
-
(2013)
PLoS One
, vol.8
-
-
Chatterjee, P.1
Choudhary, G.S.2
Sharma, A.3
Singh, K.4
Heston, W.D.5
Ciezki, J.6
Klein, E.A.7
Almasan, A.8
-
172
-
-
79953313615
-
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers
-
21300766, et al.,; PMID
-
Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011; 71:2632-42; PMID:21300766; http://dx.doi.org/10.1158/0008-5472.CAN-10-1120
-
(2011)
Cancer Res
, vol.71
, pp. 2632-2642
-
-
Vilar, E.1
Bartnik, C.M.2
Stenzel, S.L.3
Raskin, L.4
Ahn, J.5
Moreno, V.6
Mukherjee, B.7
Iniesta, M.D.8
Morgan, M.A.9
Rennert, G.10
-
173
-
-
84891834093
-
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells
-
24215868,; PMID
-
McPherson LA, Shen Y, Ford JM. Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. Cancer Lett 2014; 343:217-23; PMID:24215868; http://dx.doi.org/10.1016/j.canlet.2013.10.034
-
(2014)
Cancer Lett
, vol.343
, pp. 217-223
-
-
McPherson, L.A.1
Shen, Y.2
Ford, J.M.3
-
174
-
-
84880326910
-
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies
-
23349304, et al.,; PMID
-
Gaymes TJ, Mohamedali AM, Patterson M, Matto N, Smith A, Kulasekararaj A, Chelliah R, Curtin N, Farzaneh F, Shall S, et al. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica 2013; 98:1397-406; PMID:23349304; http://dx.doi.org/10.3324/haematol.2012.079251
-
(2013)
Haematologica
, vol.98
, pp. 1397-1406
-
-
Gaymes, T.J.1
Mohamedali, A.M.2
Patterson, M.3
Matto, N.4
Smith, A.5
Kulasekararaj, A.6
Chelliah, R.7
Curtin, N.8
Farzaneh, F.9
Shall, S.10
-
175
-
-
84863994288
-
Dissecting the heterogeneity of triple-negative breast cancer
-
22454417, et al.,; PMID
-
Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Jr., Ellis P, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012; 30:1879-87; PMID:22454417; http://dx.doi.org/10.1200/JCO.2011.38.2010
-
(2012)
J Clin Oncol
, vol.30
, pp. 1879-1887
-
-
Metzger-Filho, O.1
Tutt, A.2
de Azambuja, E.3
Saini, K.S.4
Viale, G.5
Loi, S.6
Bradbury, I.7
Bliss, J.M.8
Azim, H.A.9
Ellis, P.10
-
176
-
-
84887960666
-
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
-
24191908,; PMID
-
Jacot W, Thezenas S, Senal R, Viglianti C, Laberenne AC, Lopez-Crapez E, Bibeau F, Bleuse JP, Romieu G, Lamy PJ. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer 2013; 13:523; PMID:24191908; http://dx.doi.org/10.1186/1471-2407-13-523
-
(2013)
BMC Cancer
, vol.13
, pp. 523
-
-
Jacot, W.1
Thezenas, S.2
Senal, R.3
Viglianti, C.4
Laberenne, A.C.5
Lopez-Crapez, E.6
Bibeau, F.7
Bleuse, J.P.8
Romieu, G.9
Lamy, P.J.10
-
177
-
-
84878594500
-
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
-
23558900,; PMID
-
Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer 2013; 108:2172-7; PMID:23558900; http://dx.doi.org/10.1038/bjc.2013.144
-
(2013)
Br J Cancer
, vol.108
, pp. 2172-2177
-
-
Lips, E.H.1
Mulder, L.2
Oonk, A.3
van der Kolk, L.E.4
Hogervorst, F.B.5
Imholz, A.L.6
Wesseling, J.7
Rodenhuis, S.8
Nederlof, P.M.9
-
178
-
-
84861323251
-
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer
-
22614657, et al.,; PMID
-
Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer 2012; 118:2787-95; PMID:22614657; http://dx.doi.org/10.1002/cncr.26576
-
(2012)
Cancer
, vol.118
, pp. 2787-2795
-
-
Hartman, A.R.1
Kaldate, R.R.2
Sailer, L.M.3
Painter, L.4
Grier, C.E.5
Endsley, R.R.6
Griffin, M.7
Hamilton, S.A.8
Frye, C.A.9
Silberman, M.A.10
-
179
-
-
79952253747
-
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer
-
21233401, et al.,; PMID
-
Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17:1082-9; PMID:21233401; http://dx.doi.org/10.1158/1078-0432.CCR-10-2560
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1082-1089
-
-
Gonzalez-Angulo, A.M.1
Timms, K.M.2
Liu, S.3
Chen, H.4
Litton, J.K.5
Potter, J.6
Lanchbury, J.S.7
Stemke-Hale, K.8
Hennessy, B.T.9
Arun, B.K.10
-
180
-
-
77957599220
-
Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer
-
20858840,; PMID
-
Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: “targeted” therapy for triple-negative breast cancer. Clin Cancer Res 2010; 16:4702-10; PMID:20858840; http://dx.doi.org/10.1158/1078-0432.CCR-10-0939
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4702-4710
-
-
Anders, C.K.1
Winer, E.P.2
Ford, J.M.3
Dent, R.4
Silver, D.P.5
Sledge, G.W.6
Carey, L.A.7
-
181
-
-
65949124480
-
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase
-
19351835,; PMID
-
Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009; 69:3589-96; PMID:19351835; http://dx.doi.org/10.1158/0008-5472.CAN-08-4016
-
(2009)
Cancer Res
, vol.69
, pp. 3589-3596
-
-
Alli, E.1
Sharma, V.B.2
Sunderesakumar, P.3
Ford, J.M.4
-
182
-
-
84923082911
-
Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair
-
25642963, et al.,; PMID
-
Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI, O'Connor KW, Konstantinopoulos PA, Elledge SJ, Boulton SJ, et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair. Nature 2015; 518:258-62; PMID:25642963; http://dx.doi.org/10.1038/nature14184
-
(2015)
Nature
, vol.518
, pp. 258-262
-
-
Ceccaldi, R.1
Liu, J.C.2
Amunugama, R.3
Hajdu, I.4
Primack, B.5
Petalcorin, M.I.6
O'Connor, K.W.7
Konstantinopoulos, P.A.8
Elledge, S.J.9
Boulton, S.J.10
-
183
-
-
84923090502
-
Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination
-
25642960,; PMID
-
Mateos-Gomez PA, Gong F, Nair N, Miller KM, Lazzerini-Denchi E, Sfeir A. Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination. Nature 2015; 518:254-7; PMID:25642960; http://dx.doi.org/10.1038/nature14157
-
(2015)
Nature
, vol.518
, pp. 254-257
-
-
Mateos-Gomez, P.A.1
Gong, F.2
Nair, N.3
Miller, K.M.4
Lazzerini-Denchi, E.5
Sfeir, A.6
-
184
-
-
84866681744
-
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition
-
22915752, et al.,; PMID
-
Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012; 2:1036-47; PMID:22915752; http://dx.doi.org/10.1158/2159-8290.CD-11-0348
-
(2012)
Cancer Discov
, vol.2
, pp. 1036-1047
-
-
Ibrahim, Y.H.1
Garcia-Garcia, C.2
Serra, V.3
He, L.4
Torres-Lockhart, K.5
Prat, A.6
Anton, P.7
Cozar, P.8
Guzman, M.9
Grueso, J.10
-
185
-
-
84866709651
-
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
-
22915751, et al.,; PMID
-
Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012; 2:1048-63; PMID:22915751; http://dx.doi.org/10.1158/2159-8290.CD-11-0336
-
(2012)
Cancer Discov
, vol.2
, pp. 1048-1063
-
-
Juvekar, A.1
Burga, L.N.2
Hu, H.3
Lunsford, E.P.4
Ibrahim, Y.H.5
Balmana, J.6
Rajendran, A.7
Papa, A.8
Spencer, K.9
Lyssiotis, C.A.10
-
186
-
-
84900421919
-
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness
-
24563619,; PMID
-
De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia 2014; 16:43-72; PMID:24563619; http://dx.doi.org/10.1593/neo.131694
-
(2014)
Neoplasia
, vol.16
, pp. 43-72
-
-
De, P.1
Sun, Y.2
Carlson, J.H.3
Friedman, L.S.4
Leyland-Jones, B.R.5
Dey, N.6
-
187
-
-
79960150694
-
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
-
21706030, et al.,; PMID
-
Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011; 17:875-82; PMID:21706030; http://dx.doi.org/10.1038/nm.2377
-
(2011)
Nat Med
, vol.17
, pp. 875-882
-
-
Johnson, N.1
Li, Y.C.2
Walton, Z.E.3
Cheng, K.A.4
Li, D.5
Rodig, S.J.6
Moreau, L.A.7
Unitt, C.8
Bronson, R.T.9
Thomas, H.D.10
-
188
-
-
84904354146
-
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice
-
24817481,; PMID
-
To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 2014; 7:698-707; PMID:24817481; http://dx.doi.org/10.1158/1940-6207.CAPR-14-0047
-
(2014)
Cancer Prev Res (Phila)
, vol.7
, pp. 698-707
-
-
To, C.1
Kim, E.H.2
Royce, D.B.3
Williams, C.R.4
Collins, R.M.5
Risingsong, R.6
Sporn, M.B.7
Liby, K.T.8
-
189
-
-
77954374334
-
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells
-
20551068,; PMID
-
Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, Helleday T. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res 2010; 70:5389-98; PMID:20551068; http://dx.doi.org/10.1158/0008-5472.CAN-09-4716
-
(2010)
Cancer Res
, vol.70
, pp. 5389-5398
-
-
Gottipati, P.1
Vischioni, B.2
Schultz, N.3
Solomons, J.4
Bryant, H.E.5
Djureinovic, T.6
Issaeva, N.7
Sleeth, K.8
Sharma, R.A.9
Helleday, T.10
-
190
-
-
84875163620
-
Cisplatin resistance associated with PARP hyperactivation
-
23554447, et al.,; PMID
-
Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res 2013; 73:2271-80; PMID:23554447; http://dx.doi.org/10.1158/0008-5472.CAN-12-3000
-
(2013)
Cancer Res
, vol.73
, pp. 2271-2280
-
-
Michels, J.1
Vitale, I.2
Galluzzi, L.3
Adam, J.4
Olaussen, K.A.5
Kepp, O.6
Senovilla, L.7
Talhaoui, I.8
Guegan, J.9
Enot, D.P.10
-
191
-
-
79960359070
-
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy
-
21719137,; PMID
-
Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 2011; 99:331-8; PMID:21719137; http://dx.doi.org/10.1016/j.radonc.2011.05.084
-
(2011)
Radiother Oncol
, vol.99
, pp. 331-338
-
-
Nowsheen, S.1
Bonner, J.A.2
Yang, E.S.3
-
192
-
-
0034733928
-
Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?
-
10856830,; PMID
-
Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000; 460:1-15; PMID:10856830; http://dx.doi.org/10.1016/S0921-8777(00)00016-1
-
(2000)
Mutat Res
, vol.460
, pp. 1-15
-
-
Shall, S.1
de Murcia, G.2
-
193
-
-
79952747328
-
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
-
21300883,; PMID
-
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011; 108:3406-11; PMID:21300883; http://dx.doi.org/10.1073/pnas.1013715108
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 3406-3411
-
-
Patel, A.G.1
Sarkaria, J.N.2
Kaufmann, S.H.3
-
194
-
-
77953291328
-
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
-
20453858, et al.,; PMID
-
Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010; 17:688-95; PMID:20453858; http://dx.doi.org/10.1038/nsmb.1831
-
(2010)
Nat Struct Mol Biol
, vol.17
, pp. 688-695
-
-
Bouwman, P.1
Aly, A.2
Escandell, J.M.3
Pieterse, M.4
Bartkova, J.5
van der Gulden, H.6
Hiddingh, S.7
Thanasoula, M.8
Kulkarni, A.9
Yang, Q.10
-
195
-
-
84868221110
-
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
-
23118055,; PMID
-
Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 2012; 72:5588-99; PMID:23118055; http://dx.doi.org/10.1158/0008-5472.CAN-12-2753
-
(2012)
Cancer Res
, vol.72
, pp. 5588-5599
-
-
Murai, J.1
Huang, S.Y.2
Das, B.B.3
Renaud, A.4
Zhang, Y.5
Doroshow, J.H.6
Ji, J.7
Takeda, S.8
Pommier, Y.9
-
196
-
-
80052168685
-
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings
-
21821475,; PMID
-
Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011; 5:387-93; PMID:21821475; http://dx.doi.org/10.1016/j.molonc.2011.07.001
-
(2011)
Mol Oncol
, vol.5
, pp. 387-393
-
-
Helleday, T.1
-
197
-
-
84936802915
-
Trapping Poly(ADP-Ribose) Polymerase
-
25758918,; PMID
-
Shen Y, Aoyagi-Scharber M, Wang B. Trapping Poly(ADP-Ribose) Polymerase. J Pharmacol Exp Ther 2015; 353:446-57; PMID:25758918; http://dx.doi.org/10.1124/jpet.114.222448
-
(2015)
J Pharmacol Exp Ther
, vol.353
, pp. 446-457
-
-
Shen, Y.1
Aoyagi-Scharber, M.2
Wang, B.3
-
198
-
-
84901218339
-
Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping vs. catalytic inhibition
-
24650937,; PMID
-
Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping vs. catalytic inhibition. J Pharmacol Exp Ther 2014; 349:408-16; PMID:24650937; http://dx.doi.org/10.1124/jpet.113.210146
-
(2014)
J Pharmacol Exp Ther
, vol.349
, pp. 408-416
-
-
Murai, J.1
Zhang, Y.2
Morris, J.3
Ji, J.4
Takeda, S.5
Doroshow, J.H.6
Pommier, Y.7
-
199
-
-
84894121635
-
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
-
24356813,; PMID
-
Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014; 13:433-43; PMID:24356813; http://dx.doi.org/10.1158/1535-7163.MCT-13-0803
-
(2014)
Mol Cancer Ther
, vol.13
, pp. 433-443
-
-
Murai, J.1
Huang, S.Y.2
Renaud, A.3
Zhang, Y.4
Ji, J.5
Takeda, S.6
Morris, J.7
Teicher, B.8
Doroshow, J.H.9
Pommier, Y.10
-
200
-
-
84907598545
-
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
-
25001612, et al.,; PMID
-
Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat 2014; 146:557-66; PMID:25001612; http://dx.doi.org/10.1007/s10549-014-3039-y
-
(2014)
Breast Cancer Res Treat
, vol.146
, pp. 557-566
-
-
Anders, C.1
Deal, A.M.2
Abramson, V.3
Liu, M.C.4
Storniolo, A.M.5
Carpenter, J.T.6
Puhalla, S.7
Nanda, R.8
Melhem-Bertrandt, A.9
Lin, N.U.10
-
201
-
-
84864400878
-
Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study
-
22634397,; PMID
-
Aghajanian C, Sill MW, Secord AA, Powell MA, Steinhoff M. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2012; 126:424-7; PMID:22634397; http://dx.doi.org/10.1016/j.ygyno.2012.05.024
-
(2012)
Gynecol Oncol
, vol.126
, pp. 424-427
-
-
Aghajanian, C.1
Sill, M.W.2
Secord, A.A.3
Powell, M.A.4
Steinhoff, M.5
-
202
-
-
84934284396
-
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
-
25139550, et al.,; PMID
-
Novello S, Besse B, Felip E, Barlesi F, Mazieres J, Zalcman G, von Pawel J, Reck M, Cappuzzo F, Ferry D, et al. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. Ann Oncol 2014; 25:2156-62; PMID:25139550; http://dx.doi.org/10.1093/annonc/mdu384
-
(2014)
Ann Oncol
, vol.25
, pp. 2156-2162
-
-
Novello, S.1
Besse, B.2
Felip, E.3
Barlesi, F.4
Mazieres, J.5
Zalcman, G.6
von Pawel, J.7
Reck, M.8
Cappuzzo, F.9
Ferry, D.10
-
203
-
-
78751610848
-
Iniparib plus chemotherapy in metastatic triple-negative breast cancer
-
21208101,; PMID
-
O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205-14; PMID:21208101; http://dx.doi.org/10.1056/NEJMoa1011418
-
(2011)
N Engl J Med
, vol.364
, pp. 205-214
-
-
O'Shaughnessy, J.1
Osborne, C.2
Pippen, J.E.3
Yoffe, M.4
Patt, D.5
Rocha, C.6
Koo, I.C.7
Sherman, B.M.8
Bradley, C.9
-
204
-
-
84912105634
-
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer
-
25349301, et al.,; PMID
-
O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, et al. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014; 32:3840-7; PMID:25349301; http://dx.doi.org/10.1200/JCO.2014.55.2984
-
(2014)
J Clin Oncol
, vol.32
, pp. 3840-3847
-
-
O'Shaughnessy, J.1
Schwartzberg, L.2
Danso, M.A.3
Miller, K.D.4
Rugo, H.S.5
Neubauer, M.6
Robert, N.7
Hellerstedt, B.8
Saleh, M.9
Richards, P.10
-
205
-
-
84921771510
-
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
-
25366685, et al.,; PMID
-
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33:244-50; PMID:25366685; http://dx.doi.org/10.1200/JCO.2014.56.2728
-
(2015)
J Clin Oncol
, vol.33
, pp. 244-250
-
-
Kaufman, B.1
Shapira-Frommer, R.2
Schmutzler, R.K.3
Audeh, M.W.4
Friedlander, M.5
Balmana, J.6
Mitchell, G.7
Fried, G.8
Stemmer, S.M.9
Hubert, A.10
-
206
-
-
67650471685
-
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
-
19553641, et al.,; PMID
-
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123-34; PMID:19553641; http://dx.doi.org/10.1056/NEJMoa0900212
-
(2009)
N Engl J Med
, vol.361
, pp. 123-134
-
-
Fong, P.C.1
Boss, D.S.2
Yap, T.A.3
Tutt, A.4
Wu, P.5
Mergui-Roelvink, M.6
Mortimer, P.7
Swaisland, H.8
Lau, A.9
O'Connor, M.J.10
-
207
-
-
84859712705
-
A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors
-
22145984, et al.,; PMID
-
Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X, et al. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci 2012; 103:504-9; PMID:22145984; http://dx.doi.org/10.1111/j.1349-7006.2011.02179.x
-
(2012)
Cancer Sci
, vol.103
, pp. 504-509
-
-
Yamamoto, N.1
Nokihara, H.2
Yamada, Y.3
Goto, Y.4
Tanioka, M.5
Shibata, T.6
Yamada, K.7
Asahina, H.8
Kawata, T.9
Shi, X.10
-
208
-
-
84906085351
-
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
-
25025963, et al.,; PMID
-
Del Conte G, Sessa C, von Moos R, Vigano L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 2014; 111:651-9; PMID:25025963; http://dx.doi.org/10.1038/bjc.2014.345
-
(2014)
Br J Cancer
, vol.111
, pp. 651-659
-
-
Del Conte, G.1
Sessa, C.2
von Moos, R.3
Vigano, L.4
Digena, T.5
Locatelli, A.6
Gallerani, E.7
Fasolo, A.8
Tessari, A.9
Cathomas, R.10
-
209
-
-
77954032829
-
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
-
20406929, et al.,; PMID
-
Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28:2512-9; PMID:20406929; http://dx.doi.org/10.1200/JCO.2009.26.9589
-
(2010)
J Clin Oncol
, vol.28
, pp. 2512-2519
-
-
Fong, P.C.1
Yap, T.A.2
Boss, D.S.3
Carden, C.P.4
Mergui-Roelvink, M.5
Gourley, C.6
De Greve, J.7
Lubinski, J.8
Shanley, S.9
Messiou, C.10
-
210
-
-
84880918621
-
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery
-
23315029, et al.,; PMID
-
Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013; 31:949-58; PMID:23315029; http://dx.doi.org/10.1007/s10637-012-9922-7
-
(2013)
Invest New Drugs
, vol.31
, pp. 949-958
-
-
Bundred, N.1
Gardovskis, J.2
Jaskiewicz, J.3
Eglitis, J.4
Paramonov, V.5
McCormack, P.6
Swaisland, H.7
Cavallin, M.8
Parry, T.9
Carmichael, J.10
-
211
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
-
20609467, et al.,; PMID
-
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235-44; PMID:20609467; http://dx.doi.org/10.1016/S0140-6736(10)60892-6
-
(2010)
Lancet
, vol.376
, pp. 235-244
-
-
Tutt, A.1
Robson, M.2
Garber, J.E.3
Domchek, S.M.4
Audeh, M.W.5
Weitzel, J.N.6
Friedlander, M.7
Arun, B.8
Loman, N.9
Schmutzler, R.K.10
-
212
-
-
84863010984
-
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
-
22203755, et al.,; PMID
-
Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30:372-9; PMID:22203755; http://dx.doi.org/10.1200/JCO.2011.36.9215
-
(2012)
J Clin Oncol
, vol.30
, pp. 372-379
-
-
Kaye, S.B.1
Lubinski, J.2
Matulonis, U.3
Ang, J.E.4
Gourley, C.5
Karlan, B.Y.6
Amnon, A.7
Bell-McGuinn, K.M.8
Chen, L.M.9
Friedlander, M.10
-
213
-
-
77955039099
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
-
20609468, et al.,; PMID
-
Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376:245-51; PMID:20609468; http://dx.doi.org/10.1016/S0140-6736(10)60893-8
-
(2010)
Lancet
, vol.376
, pp. 245-251
-
-
Audeh, M.W.1
Carmichael, J.2
Penson, R.T.3
Friedlander, M.4
Powell, B.5
Bell-McGuinn, K.M.6
Scott, C.7
Weitzel, J.N.8
Oaknin, A.9
Loman, N.10
-
214
-
-
80052389761
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
-
21862407, et al.,; PMID
-
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12:852-61; PMID:21862407; http://dx.doi.org/10.1016/S1470-2045(11)70214-5
-
(2011)
Lancet Oncol
, vol.12
, pp. 852-861
-
-
Gelmon, K.A.1
Tischkowitz, M.2
Mackay, H.3
Swenerton, K.4
Robidoux, A.5
Tonkin, K.6
Hirte, H.7
Huntsman, D.8
Clemons, M.9
Gilks, B.10
-
215
-
-
84859523588
-
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
-
22452356, et al.,; PMID
-
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366:1382-92; PMID:22452356; http://dx.doi.org/10.1056/NEJMoa1105535
-
(2012)
N Engl J Med
, vol.366
, pp. 1382-1392
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
Friedlander, M.4
Vergote, I.5
Rustin, G.6
Scott, C.7
Meier, W.8
Shapira-Frommer, R.9
Safra, T.10
-
216
-
-
84920855943
-
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
-
25374341, et al.,; PMID
-
Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer 2014; 14:813; PMID:25374341; http://dx.doi.org/10.1186/1471-2407-14-813
-
(2014)
BMC Cancer
, vol.14
, pp. 813
-
-
Choy, E.1
Butrynski, J.E.2
Harmon, D.C.3
Morgan, J.A.4
George, S.5
Wagner, A.J.6
D'Adamo, D.7
Cote, G.M.8
Flamand, Y.9
Benes, C.H.10
-
217
-
-
84880777712
-
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
-
23810788, et al.,; PMID
-
Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013; 14:882-92; PMID:23810788; http://dx.doi.org/10.1016/S1470-2045(13)70240-7
-
(2013)
Lancet Oncol
, vol.14
, pp. 882-892
-
-
Sandhu, S.K.1
Schelman, W.R.2
Wilding, G.3
Moreno, V.4
Baird, R.D.5
Miranda, S.6
Hylands, L.7
Riisnaes, R.8
Forster, M.9
Omlin, A.10
-
218
-
-
84930047827
-
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation–An NRG Oncology/Gynecologic Oncology Group study
-
25818403, et al.,; 137:386-91; PMID
-
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation–An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015; 137:386-91; PMID:25818403; doi: 10.1016/j.ygyno.2015.03.042
-
(2015)
Gynecol Oncol
-
-
Coleman, R.L.1
Sill, M.W.2
Bell-McGuinn, K.3
Aghajanian, C.4
Gray, H.J.5
Tewari, K.S.6
Rubin, S.C.7
Rutherford, T.J.8
Chan, J.K.9
Chen, A.10
-
219
-
-
84903547236
-
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
-
24882434, et al.,; PMID
-
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15:852-61; PMID:24882434; http://dx.doi.org/10.1016/S1470-2045(14)70228-1
-
(2014)
Lancet Oncol
, vol.15
, pp. 852-861
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
Friedlander, M.4
Vergote, I.5
Rustin, G.6
Scott, C.L.7
Meier, W.8
Shapira-Frommer, R.9
Safra, T.10
-
220
-
-
3843113670
-
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
-
15288283,; PMID
-
Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40:1825-36; PMID:15288283; http://dx.doi.org/10.1016/j.ejca.2004.04.030
-
(2004)
Eur J Cancer
, vol.40
, pp. 1825-1836
-
-
Eggermont, A.M.1
Kirkwood, J.M.2
-
221
-
-
79952281417
-
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
-
21326243, et al.,; PMID
-
Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011; 104:750-5; PMID:21326243; http://dx.doi.org/10.1038/bjc.2011.8
-
(2011)
Br J Cancer
, vol.104
, pp. 750-755
-
-
Khan, O.A.1
Gore, M.2
Lorigan, P.3
Stone, J.4
Greystoke, A.5
Burke, W.6
Carmichael, J.7
Watson, A.J.8
McGown, G.9
Thorncroft, M.10
-
222
-
-
84865704717
-
Prognostic impact of vitamin B6 metabolism in lung cancer
-
22854025, et al.,; PMID
-
Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2:257-69; PMID:22854025; http://dx.doi.org/10.1016/j.celrep.2012.06.017
-
(2012)
Cell Rep
, vol.2
, pp. 257-269
-
-
Galluzzi, L.1
Vitale, I.2
Senovilla, L.3
Olaussen, K.A.4
Pinna, G.5
Eisenberg, T.6
Goubar, A.7
Martins, I.8
Michels, J.9
Kratassiouk, G.10
-
223
-
-
84859771379
-
Molecular mechanisms of cisplatin resistance
-
21892204,; PMID
-
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
-
(2012)
Oncogene
, vol.31
, pp. 1869-1883
-
-
Galluzzi, L.1
Senovilla, L.2
Vitale, I.3
Michels, J.4
Martins, I.5
Kepp, O.6
Castedo, M.7
Kroemer, G.8
-
224
-
-
46749123261
-
Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
-
18362892, et al.,; PMID
-
Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27:4221-32; PMID:18362892; http://dx.doi.org/10.1038/onc.2008.63
-
(2008)
Oncogene
, vol.27
, pp. 4221-4232
-
-
Tajeddine, N.1
Galluzzi, L.2
Kepp, O.3
Hangen, E.4
Morselli, E.5
Senovilla, L.6
Araujo, N.7
Pinna, G.8
Larochette, N.9
Zamzami, N.10
-
225
-
-
84885956128
-
Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells
-
24228232,; PMID
-
Cirone M, Garufi A, Di Renzo L, Granato M, Faggioni A, D'Orazi G. Zinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells. Oncoimmunology 2013; 2:e26198; PMID:24228232; http://dx.doi.org/10.4161/onci.26198
-
(2013)
Oncoimmunology
, vol.2
, pp. e26198
-
-
Cirone, M.1
Garufi, A.2
Di Renzo, L.3
Granato, M.4
Faggioni, A.5
D'Orazi, G.6
-
226
-
-
12844287650
-
Combined modality therapy of gemcitabine and radiation
-
15632251,; PMID
-
Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality therapy of gemcitabine and radiation. Oncologist 2005; 10:34-51; PMID:15632251; http://dx.doi.org/10.1634/theoncologist.10-1-34
-
(2005)
Oncologist
, vol.10
, pp. 34-51
-
-
Pauwels, B.1
Korst, A.E.2
Lardon, F.3
Vermorken, J.B.4
-
227
-
-
0037268904
-
Role of gemcitabine in the treatment of advanced and metastatic breast cancer
-
12697958,; PMID
-
Heinemann V. Role of gemcitabine in the treatment of advanced and metastatic breast cancer. Oncology 2003; 64:191-206; PMID:12697958; http://dx.doi.org/10.1159/000069315
-
(2003)
Oncology
, vol.64
, pp. 191-206
-
-
Heinemann, V.1
-
228
-
-
84859864115
-
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors
-
22371451, et al.,; PMID
-
Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18:2344-51; PMID:22371451; http://dx.doi.org/10.1158/1078-0432.CCR-11-2425
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2344-2351
-
-
Rajan, A.1
Carter, C.A.2
Kelly, R.J.3
Gutierrez, M.4
Kummar, S.5
Szabo, E.6
Yancey, M.A.7
Ji, J.8
Mannargudi, B.9
Woo, S.10
-
229
-
-
77956185195
-
Therapy of small cell lung cancer with emphasis on oral topotecan
-
20576312, et al.,; PMID
-
Pirker R, Berzinec P, Brincat S, Kasan P, Ostoros G, Pesek M, Plate S, Purkalne G, Rooneem R, Skrickova J, et al. Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer 2010; 70:7-13; PMID:20576312; http://dx.doi.org/10.1016/j.lungcan.2010.05.020
-
(2010)
Lung Cancer
, vol.70
, pp. 7-13
-
-
Pirker, R.1
Berzinec, P.2
Brincat, S.3
Kasan, P.4
Ostoros, G.5
Pesek, M.6
Plate, S.7
Purkalne, G.8
Rooneem, R.9
Skrickova, J.10
-
230
-
-
84866564290
-
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
-
21590367,; PMID
-
Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, Cassidy J. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs 2012; 30:1493-500; PMID:21590367; http://dx.doi.org/10.1007/s10637-011-9682-9
-
(2012)
Invest New Drugs
, vol.30
, pp. 1493-1500
-
-
Samol, J.1
Ranson, M.2
Scott, E.3
Macpherson, E.4
Carmichael, J.5
Thomas, A.6
Cassidy, J.7
-
231
-
-
80052238687
-
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas
-
21795476, et al.,; PMID
-
Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011; 71:5626-34; PMID:21795476; http://dx.doi.org/10.1158/0008-5472.CAN-11-1227
-
(2011)
Cancer Res
, vol.71
, pp. 5626-5634
-
-
Kummar, S.1
Chen, A.2
Ji, J.3
Zhang, Y.4
Reid, J.M.5
Ames, M.6
Jia, L.7
Weil, M.8
Speranza, G.9
Murgo, A.J.10
-
232
-
-
84924426159
-
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG oncology/gynecologic oncology group study
-
25594147,; PMID
-
Kunos C, Deng W, Dawson D, Lea JS, Zanotti KM, Gray HJ, Bender DP, Guaglianone PP, Carter JS, Moore KN. A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG oncology/gynecologic oncology group study. Int J Gynecol Cancer 2015; 25:484-92; PMID:25594147; http://dx.doi.org/10.1097/IGC.0000000000000380
-
(2015)
Int J Gynecol Cancer
, vol.25
, pp. 484-492
-
-
Kunos, C.1
Deng, W.2
Dawson, D.3
Lea, J.S.4
Zanotti, K.M.5
Gray, H.J.6
Bender, D.P.7
Guaglianone, P.P.8
Carter, J.S.9
Moore, K.N.10
-
233
-
-
84925969599
-
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report
-
24908656, et al.,; PMID
-
Su JM, Thompson P, Adesina A, Li XN, Kilburn L, Onar-Thomas A, Kocak M, Chyla B, McKeegan E, Warren KE, et al. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol 2014; 16:1661-8; PMID:24908656; http://dx.doi.org/10.1093/neuonc/nou103
-
(2014)
Neuro Oncol
, vol.16
, pp. 1661-1668
-
-
Su, J.M.1
Thompson, P.2
Adesina, A.3
Li, X.N.4
Kilburn, L.5
Onar-Thomas, A.6
Kocak, M.7
Chyla, B.8
McKeegan, E.9
Warren, K.E.10
-
234
-
-
68849090462
-
A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma
-
19440934,; PMID
-
Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 2009; 27:756-63; PMID:19440934; http://dx.doi.org/10.1080/07357900802709159
-
(2009)
Cancer Invest
, vol.27
, pp. 756-763
-
-
Bedikian, A.Y.1
Papadopoulos, N.E.2
Kim, K.B.3
Hwu, W.J.4
Homsi, J.5
Glass, M.R.6
Cain, S.7
Rudewicz, P.8
Vernillet, L.9
Hwu, P.10
-
235
-
-
0036856459
-
Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine
-
12435845,; PMID
-
Margison GP, Santibanez Koref MF, Povey AC. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis 2002; 17:483-7; PMID:12435845; http://dx.doi.org/10.1093/mutage/17.6.483
-
(2002)
Mutagenesis
, vol.17
, pp. 483-487
-
-
Margison, G.P.1
Santibanez Koref, M.F.2
Povey, A.C.3
-
236
-
-
0035559629
-
Temozolomide: a novel oral alkylating agent
-
12113120,; PMID
-
Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1:13-9; PMID:12113120; http://dx.doi.org/10.1586/14737140.1.1.13
-
(2001)
Expert Rev Anticancer Ther
, vol.1
, pp. 13-19
-
-
Danson, S.J.1
Middleton, M.R.2
-
237
-
-
84877920585
-
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
-
23423489, et al.,; PMID
-
Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, et al. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol 2013; 71:1191-9; PMID:23423489; http://dx.doi.org/10.1007/s00280-013-2113-1
-
(2013)
Cancer Chemother Pharmacol
, vol.71
, pp. 1191-1199
-
-
Plummer, R.1
Lorigan, P.2
Steven, N.3
Scott, L.4
Middleton, M.R.5
Wilson, R.H.6
Mulligan, E.7
Curtin, N.8
Wang, D.9
Dewji, R.10
-
238
-
-
84905183020
-
Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors
-
24827126, et al.,; PMID
-
Balmana J, Tung NM, Isakoff SJ, Grana B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol 2014; 25:1656-63; PMID:24827126; http://dx.doi.org/10.1093/annonc/mdu187
-
(2014)
Ann Oncol
, vol.25
, pp. 1656-1663
-
-
Balmana, J.1
Tung, N.M.2
Isakoff, S.J.3
Grana, B.4
Ryan, P.D.5
Saura, C.6
Lowe, E.S.7
Frewer, P.8
Winer, E.9
Baselga, J.10
-
239
-
-
84877805593
-
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
-
23483678,; PMID
-
Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW, Hamid O. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:23483678; http://dx.doi.org/10.4161/onci.23033
-
(2013)
Oncoimmunology
, vol.2
, pp. e23033
-
-
Vonderheide, R.H.1
Burg, J.M.2
Mick, R.3
Trosko, J.A.4
Li, D.5
Shaik, M.N.6
Tolcher, A.W.7
Hamid, O.8
-
240
-
-
0027427932
-
New cisplatin analogues in development. A review
-
7693428,; PMID
-
Weiss RB, Christian MC. New cisplatin analogues in development. A review. Drugs 1993; 46:360-77; PMID:7693428; http://dx.doi.org/10.2165/00003495-199346030-00003
-
(1993)
Drugs
, vol.46
, pp. 360-377
-
-
Weiss, R.B.1
Christian, M.C.2
-
241
-
-
0022337278
-
Preclinical studies identifying carboplatin as a viable cisplatin alternative
-
3910219,; PMID
-
Harrap KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 1985; 12:21-33; PMID:3910219; http://dx.doi.org/10.1016/0305-7372(85)90015-5
-
(1985)
Cancer Treat Rev
, vol.12
, pp. 21-33
-
-
Harrap, K.R.1
-
242
-
-
84905187284
-
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses
-
24842883, et al.,; PMID
-
Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106:dju089; PMID:24842883
-
(2014)
J Natl Cancer Inst
, vol.106
, pp. dju089
-
-
Lee, J.M.1
Hays, J.L.2
Annunziata, C.M.3
Noonan, A.M.4
Minasian, L.5
Zujewski, J.A.6
Yu, M.7
Gordon, N.8
Ji, J.9
Sissung, T.M.10
-
243
-
-
84872068442
-
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
-
22811009,; PMID
-
White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2013; 119:339-47; PMID:22811009; http://dx.doi.org/10.1002/cncr.27745
-
(2013)
Cancer
, vol.119
, pp. 339-347
-
-
White, D.1
Kassim, A.2
Bhaskar, B.3
Yi, J.4
Wamstad, K.5
Paton, V.E.6
-
244
-
-
84886943665
-
The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
-
23762809,; PMID
-
Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2013; 2:e24436; PMID:23762809; http://dx.doi.org/10.4161/onci.24436
-
(2013)
Oncoimmunology
, vol.2
, pp. e24436
-
-
Mansfield, A.S.1
Nevala, W.K.2
Lieser, E.A.3
Leontovich, A.A.4
Markovic, S.N.5
-
245
-
-
84886313817
-
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo
-
23170253,; PMID
-
Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PT. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 2012; 1:1048-60; PMID:23170253; http://dx.doi.org/10.4161/onci.20708
-
(2012)
Oncoimmunology
, vol.1
, pp. 1048-1060
-
-
Foy, K.C.1
Miller, M.J.2
Moldovan, N.3
Carson Iii, W.E.4
Kaumaya, P.T.5
-
246
-
-
61349124193
-
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the national cancer institute of canada clinical trials group
-
19091548,; PMID
-
Goss G, Shepherd FA, Laurie S, Gauthier I, Leighl N, Chen E, Feld R, Powers J, Seymour L. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the national cancer institute of canada clinical trials group. Eur J Cancer 2009; 45:782-8; PMID:19091548; http://dx.doi.org/10.1016/j.ejca.2008.10.022
-
(2009)
Eur J Cancer
, vol.45
, pp. 782-788
-
-
Goss, G.1
Shepherd, F.A.2
Laurie, S.3
Gauthier, I.4
Leighl, N.5
Chen, E.6
Feld, R.7
Powers, J.8
Seymour, L.9
-
247
-
-
34547666982
-
The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model
-
17671138,; PMID
-
Gomez-Rivera F, Santillan-Gomez AA, Younes MN, Kim S, Fooshee D, Zhao M, Jasser SA, Myers JN. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin Cancer Res 2007; 13:4519-27; PMID:17671138; http://dx.doi.org/10.1158/1078-0432.CCR-06-2636
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4519-4527
-
-
Gomez-Rivera, F.1
Santillan-Gomez, A.A.2
Younes, M.N.3
Kim, S.4
Fooshee, D.5
Zhao, M.6
Jasser, S.A.7
Myers, J.N.8
-
248
-
-
20144370978
-
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
-
15899831, et al.,; PMID
-
Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65:4389-400; PMID:15899831; http://dx.doi.org/10.1158/0008-5472.CAN-04-4409
-
(2005)
Cancer Res
, vol.65
, pp. 4389-4400
-
-
Wedge, S.R.1
Kendrew, J.2
Hennequin, L.F.3
Valentine, P.J.4
Barry, S.T.5
Brave, S.R.6
Smith, N.R.7
James, N.H.8
Dukes, M.9
Curwen, J.O.10
-
249
-
-
84856509572
-
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
-
22223088,; PMID
-
Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, Ranson M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012; 106:468-74; PMID:22223088; http://dx.doi.org/10.1038/bjc.2011.555
-
(2012)
Br J Cancer
, vol.106
, pp. 468-474
-
-
Dean, E.1
Middleton, M.R.2
Pwint, T.3
Swaisland, H.4
Carmichael, J.5
Goodege-Kunwar, P.6
Ranson, M.7
-
250
-
-
84883054717
-
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
-
23810467, et al.,; PMID
-
Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013; 49:2972-8; PMID:23810467; http://dx.doi.org/10.1016/j.ejca.2013.05.020
-
(2013)
Eur J Cancer
, vol.49
, pp. 2972-2978
-
-
Liu, J.F.1
Tolaney, S.M.2
Birrer, M.3
Fleming, G.F.4
Buss, M.K.5
Dahlberg, S.E.6
Lee, H.7
Whalen, C.8
Tyburski, K.9
Winer, E.10
-
251
-
-
84908134454
-
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
-
25218906, et al.,; PMID
-
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15:1207-14; PMID:25218906; http://dx.doi.org/10.1016/S1470-2045(14)70391-2
-
(2014)
Lancet Oncol
, vol.15
, pp. 1207-1214
-
-
Liu, J.F.1
Barry, W.T.2
Birrer, M.3
Lee, J.M.4
Buckanovich, R.J.5
Fleming, G.F.6
Rimel, B.7
Buss, M.K.8
Nattam, S.9
Hurteau, J.10
-
252
-
-
48549095021
-
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone
-
18593931, et al.,; PMID
-
Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-8; PMID:18593931; http://dx.doi.org/10.1158/0008-5472.CAN-08-0237
-
(2008)
Cancer Res
, vol.68
, pp. 5301-5308
-
-
Hoffmann, J.1
Vitale, I.2
Buchmann, B.3
Galluzzi, L.4
Schwede, W.5
Senovilla, L.6
Skuballa, W.7
Vivet, S.8
Lichtner, R.B.9
Vicencio, J.M.10
-
253
-
-
84885954101
-
Mitosis-targeting therapies: a troubleshooting guide
-
23583638,; PMID
-
Domenech E, Malumbres M. Mitosis-targeting therapies: a troubleshooting guide. Curr Opin Pharmacol 2013; 13:519-28; PMID:23583638; http://dx.doi.org/10.1016/j.coph.2013.03.011
-
(2013)
Curr Opin Pharmacol
, vol.13
, pp. 519-528
-
-
Domenech, E.1
Malumbres, M.2
-
254
-
-
1942438028
-
Microtubules as a target for anticancer drugs
-
15057285,; PMID
-
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65; PMID:15057285; http://dx.doi.org/10.1038/nrc1317
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 253-265
-
-
Jordan, M.A.1
Wilson, L.2
-
255
-
-
84884509017
-
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
-
24063698,; PMID
-
Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013; 15:R88; PMID:24063698; http://dx.doi.org/10.1186/bcr3484
-
(2013)
Breast Cancer Res
, vol.15
, pp. R88
-
-
Dent, R.A.1
Lindeman, G.J.2
Clemons, M.3
Wildiers, H.4
Chan, A.5
McCarthy, N.J.6
Singer, C.F.7
Lowe, E.S.8
Watkins, C.L.9
Carmichael, J.10
-
256
-
-
84924760015
-
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
-
25481791, et al.,; PMID
-
Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Spacek J, Vuylsteke P, Hirte H, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16:87-97; PMID:25481791; http://dx.doi.org/10.1016/S1470-2045(14)71135-0
-
(2015)
Lancet Oncol
, vol.16
, pp. 87-97
-
-
Oza, A.M.1
Cibula, D.2
Benzaquen, A.O.3
Poole, C.4
Mathijssen, R.H.5
Sonke, G.S.6
Colombo, N.7
Spacek, J.8
Vuylsteke, P.9
Hirte, H.10
-
257
-
-
84890283544
-
The Janus face of cyclophosphamide: a sterile inflammatory response that potentiates cancer immunotherapy
-
24244905,; PMID
-
Ziccheddu G, Proietti E, Moschella F. The Janus face of cyclophosphamide: a sterile inflammatory response that potentiates cancer immunotherapy. Oncoimmunology 2013; 2:e25789; PMID:24244905; http://dx.doi.org/10.4161/onci.25789
-
(2013)
Oncoimmunology
, vol.2
, pp. e25789
-
-
Ziccheddu, G.1
Proietti, E.2
Moschella, F.3
-
258
-
-
84880936480
-
Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
-
23482454,; PMID
-
Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2013; 2:e22246; PMID:23482454; http://dx.doi.org/10.4161/onci.22246
-
(2013)
Oncoimmunology
, vol.2
, pp. e22246
-
-
Walter, S.1
Weinschenk, T.2
Reinhardt, C.3
Singh-Jasuja, H.4
-
259
-
-
84902590233
-
Synergistic antitumor effects of a TGFbeta inhibitor and cyclophosphamide
-
25050195,; PMID
-
Chen X, Wakefield LM, Oppenheim JJ. Synergistic antitumor effects of a TGFbeta inhibitor and cyclophosphamide. Oncoimmunology 2014; 3:e28247; PMID:25050195; http://dx.doi.org/10.4161/onci.28247
-
(2014)
Oncoimmunology
, vol.3
, pp. e28247
-
-
Chen, X.1
Wakefield, L.M.2
Oppenheim, J.J.3
-
260
-
-
84919920835
-
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
-
24764124, et al.,; PMID
-
Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, et al. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2014; 32:904-12; PMID:24764124; http://dx.doi.org/10.1007/s10637-014-0099-0
-
(2014)
Invest New Drugs
, vol.32
, pp. 904-912
-
-
Hussain, M.1
Carducci, M.A.2
Slovin, S.3
Cetnar, J.4
Qian, J.5
McKeegan, E.M.6
Refici-Buhr, M.7
Chyla, B.8
Shepherd, S.P.9
Giranda, V.L.10
-
261
-
-
84863236347
-
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas
-
22307137, et al.,; PMID
-
Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012; 18:1726-34; PMID:22307137; http://dx.doi.org/10.1158/1078-0432.CCR-11-2821
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1726-1734
-
-
Kummar, S.1
Ji, J.2
Morgan, R.3
Lenz, H.J.4
Puhalla, S.L.5
Belani, C.P.6
Gandara, D.R.7
Allen, D.8
Kiesel, B.9
Beumer, J.H.10
-
262
-
-
84920671472
-
A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis
-
25355929, et al.,; PMID
-
Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scardina A, Joffe C, Petito E, Hacker-Prietz A, Kinders RJ, et al. A phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res 2015; 21:68-76; PMID:25355929; http://dx.doi.org/10.1158/1078-0432.CCR-14-1552
-
(2015)
Clin Cancer Res
, vol.21
, pp. 68-76
-
-
Reiss, K.A.1
Herman, J.M.2
Zahurak, M.3
Brade, A.4
Dawson, L.A.5
Scardina, A.6
Joffe, C.7
Petito, E.8
Hacker-Prietz, A.9
Kinders, R.J.10
-
263
-
-
84938301703
-
Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study
-
25682091, et al.,; 122:409-17; PMID
-
Mehta MP, Wang D, Wang F, Kleinberg L, Brade A, Robins HI, Turaka A, Leahy T, Medina D, Xiong H, et al. Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. J Neurooncol 2015; 122:409-17; PMID:25682091; http://dx.doi.org/10.1007/s11060-015-1733-1
-
(2015)
J Neurooncol
-
-
Mehta, M.P.1
Wang, D.2
Wang, F.3
Kleinberg, L.4
Brade, A.5
Robins, H.I.6
Turaka, A.7
Leahy, T.8
Medina, D.9
Xiong, H.10
-
264
-
-
84907597103
-
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
-
24880570,; PMID
-
Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol 2014; 74:257-65; PMID:24880570; http://dx.doi.org/10.1007/s00280-014-2486-9
-
(2014)
Cancer Chemother Pharmacol
, vol.74
, pp. 257-265
-
-
Plummer, R.1
Stephens, P.2
Aissat-Daudigny, L.3
Cambois, A.4
Moachon, G.5
Brown, P.D.6
Campone, M.7
-
265
-
-
59449085305
-
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
-
19047122, et al.,; PMID
-
Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14:7917-23; PMID:19047122; http://dx.doi.org/10.1158/1078-0432.CCR-08-1223
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7917-7923
-
-
Plummer, R.1
Jones, C.2
Middleton, M.3
Wilson, R.4
Evans, J.5
Olsen, A.6
Curtin, N.7
Boddy, A.8
McHugh, P.9
Newell, D.10
-
266
-
-
84927535927
-
Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer
-
25589624, et al.,; PMID
-
Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Jr., Szabo PM, Youn A, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res 2015; 21:1574-82; PMID:25589624; http://dx.doi.org/10.1158/1078-0432.CCR-14-2565
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1574-1582
-
-
Kummar, S.1
Oza, A.M.2
Fleming, G.F.3
Sullivan, D.M.4
Gandara, D.R.5
Naughton, M.J.6
Villalona-Calero, M.A.7
Morgan, R.J.8
Szabo, P.M.9
Youn, A.10
-
267
-
-
14844303761
-
Capecitabine: a review
-
15763604,; PMID
-
Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27:23-44; PMID:15763604; http://dx.doi.org/10.1016/j.clinthera.2005.01.005
-
(2005)
Clin Ther
, vol.27
, pp. 23-44
-
-
Walko, C.M.1
Lindley, C.2
-
268
-
-
66349133435
-
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach
-
19423674,; PMID
-
Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G, Vinante O, Pronzato P, Pappagallo G. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009; 14:497-510; PMID:19423674; http://dx.doi.org/10.1634/theoncologist.2008-0260
-
(2009)
Oncologist
, vol.14
, pp. 497-510
-
-
Grossi, F.1
Aita, M.2
Defferrari, C.3
Rosetti, F.4
Brianti, A.5
Fasola, G.6
Vinante, O.7
Pronzato, P.8
Pappagallo, G.9
-
269
-
-
0026327465
-
Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules
-
1784631,; PMID
-
Himes RH. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 1991; 51:257-67; PMID:1784631; http://dx.doi.org/10.1016/0163-7258(91)90081-V
-
(1991)
Pharmacol Ther
, vol.51
, pp. 257-267
-
-
Himes, R.H.1
-
270
-
-
84947075775
-
P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)
-
et al
-
Roche H, Blum J, Eiermann W, Im YH, Martin M, Mina L, Rugo H, Visco F, Zhang C, Lokker N, et al. P1.01A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA). Ann Oncol 2015; 26 2:ii16
-
(2015)
Ann Oncol
, vol.26
, Issue.2
, pp. ii16
-
-
Roche, H.1
Blum, J.2
Eiermann, W.3
Im, Y.H.4
Martin, M.5
Mina, L.6
Rugo, H.7
Visco, F.8
Zhang, C.9
Lokker, N.10
-
271
-
-
42949112558
-
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
-
18332475, et al.,; PMID
-
Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26:1948-55; PMID:18332475; http://dx.doi.org/10.1200/JCO.2007.11.6798
-
(2008)
J Clin Oncol
, vol.26
, pp. 1948-1955
-
-
Goss, P.E.1
Ingle, J.N.2
Pater, J.L.3
Martino, S.4
Robert, N.J.5
Muss, H.B.6
Piccart, M.J.7
Castiglione, M.8
Shepherd, L.E.9
Pritchard, K.I.10
-
272
-
-
37449028688
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
-
18083636,; PMID
-
Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9:45-53; PMID:18083636; http://dx.doi.org/10.1016/S1470-2045(07)70385-6
-
(2008)
Lancet Oncol
, vol.9
, pp. 45-53
-
-
Forbes, J.F.1
Cuzick, J.2
Buzdar, A.3
Howell, A.4
Tobias, J.S.5
Baum, M.6
-
273
-
-
11444251764
-
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
-
15639680,; PMID
-
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2; PMID:15639680; http://dx.doi.org/10.1016/S0140-6736(05)74803-0
-
(2005)
Lancet
, vol.365
, pp. 60-62
-
-
Howell, A.1
Cuzick, J.2
Baum, M.3
Buzdar, A.4
Dowsett, M.5
Forbes, J.F.6
Hoctin-Boes, G.7
Houghton, J.8
Locker, G.Y.9
Tobias, J.S.10
-
274
-
-
85203363507
-
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
-
21802721, et al.,; PMID
-
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771-84; PMID:21802721; http://dx.doi.org/10.1016/S0140-6736(11)60993-8
-
(2011)
Lancet
, vol.378
, pp. 771-784
-
-
Davies, C.1
Godwin, J.2
Gray, R.3
Clarke, M.4
Cutter, D.5
Darby, S.6
McGale, P.7
Pan, H.C.8
Taylor, C.9
Wang, Y.C.10
-
275
-
-
84897949607
-
Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma
-
24493717, et al.,; PMID
-
Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol 2014; 32:745-51; PMID:24493717; http://dx.doi.org/10.1200/JCO.2013.49.9525
-
(2014)
J Clin Oncol
, vol.32
, pp. 745-751
-
-
Kim, D.J.1
Kim, J.2
Spaunhurst, K.3
Montoya, J.4
Khodosh, R.5
Chandra, K.6
Fu, T.7
Gilliam, A.8
Molgo, M.9
Beachy, P.A.10
-
276
-
-
84876411054
-
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer
-
23546045,; PMID
-
Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, Sebree R, Smith R, Aftab BT, Huang P, Liu JO. Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol 2013; 8:619-23; PMID:23546045
-
(2013)
J Thorac Oncol
, vol.8
, pp. 619-623
-
-
Rudin, C.M.1
Brahmer, J.R.2
Juergens, R.A.3
Hann, C.L.4
Ettinger, D.S.5
Sebree, R.6
Smith, R.7
Aftab, B.T.8
Huang, P.9
Liu, J.O.10
-
277
-
-
77950492233
-
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
-
20385363, et al.,; PMID
-
Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010; 17:388-99; PMID:20385363; http://dx.doi.org/10.1016/j.ccr.2010.02.027
-
(2010)
Cancer Cell
, vol.17
, pp. 388-399
-
-
Kim, J.1
Tang, J.Y.2
Gong, R.3
Kim, J.4
Lee, J.J.5
Clemons, K.V.6
Chong, C.R.7
Chang, K.S.8
Fereshteh, M.9
Gardner, D.10
-
278
-
-
0042163137
-
Pharmacokinetic interactions with rifampicin : clinical relevance
-
12882588,; PMID
-
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42:819-50; PMID:12882588; http://dx.doi.org/10.2165/00003088-200342090-00003
-
(2003)
Clin Pharmacokinet
, vol.42
, pp. 819-850
-
-
Niemi, M.1
Backman, J.T.2
Fromm, M.F.3
Neuvonen, P.J.4
Kivisto, K.T.5
-
279
-
-
84995413066
-
Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma
-
25628925,; PMID
-
Liao H, Huang Y, Guo B, Liang B, Liu X, Ou H, Jiang C, Li X, Yang D. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. Am J Cancer Res 2015; 5:125-39; PMID:25628925
-
(2015)
Am J Cancer Res
, vol.5
, pp. 125-139
-
-
Liao, H.1
Huang, Y.2
Guo, B.3
Liang, B.4
Liu, X.5
Ou, H.6
Jiang, C.7
Li, X.8
Yang, D.9
-
280
-
-
84875184123
-
Discovery of 4-amino-N-; [(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo; [2,3-d]pyrimidin -4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases
-
23394218, et al.,; PMID
-
Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R, et al. Discovery of 4-amino-N-; [(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo; [2,3-d]pyrimidin -4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 2013; 56:2059-73; PMID:23394218; http://dx.doi.org/10.1021/jm301762v
-
(2013)
J Med Chem
, vol.56
, pp. 2059-2073
-
-
Addie, M.1
Ballard, P.2
Buttar, D.3
Crafter, C.4
Currie, G.5
Davies, B.R.6
Debreczeni, J.7
Dry, H.8
Dudley, P.9
Greenwood, R.10
-
281
-
-
84873731572
-
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014
-
23375793,; PMID
-
Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013; 23:1212-6; PMID:23375793; http://dx.doi.org/10.1016/j.bmcl.2013.01.019
-
(2013)
Bioorg Med Chem Lett
, vol.23
, pp. 1212-1216
-
-
Pike, K.G.1
Malagu, K.2
Hummersone, M.G.3
Menear, K.A.4
Duggan, H.M.5
Gomez, S.6
Martin, N.M.7
Ruston, L.8
Pass, S.L.9
Pass, M.10
-
282
-
-
84862738897
-
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
-
22294718, et al.,; PMID
-
Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012; 11:873-87; PMID:22294718; http://dx.doi.org/10.1158/1535-7163.MCT-11-0824-T
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 873-887
-
-
Davies, B.R.1
Greenwood, H.2
Dudley, P.3
Crafter, C.4
Yu, D.H.5
Zhang, J.6
Li, J.7
Gao, B.8
Ji, Q.9
Maynard, J.10
-
283
-
-
80054737055
-
Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer
-
24900266, et al.,; PMID
-
Burger MT, Pecchi S, Wagman A, Ni ZJ, Knapp M, Hendrickson T, Atallah G, Pfister K, Zhang Y, Bartulis S, et al. Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer. ACS Med Chem Lett 2011; 2:774-9; PMID:24900266; http://dx.doi.org/10.1021/ml200156t
-
(2011)
ACS Med Chem Lett
, vol.2
, pp. 774-779
-
-
Burger, M.T.1
Pecchi, S.2
Wagman, A.3
Ni, Z.J.4
Knapp, M.5
Hendrickson, T.6
Atallah, G.7
Pfister, K.8
Zhang, Y.9
Bartulis, S.10
-
284
-
-
56349121553
-
CYP17 inhibition as a hormonal strategy for prostate cancer
-
18985049,; PMID
-
Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008; 5:610-20; PMID:18985049; http://dx.doi.org/10.1038/ncpuro1237
-
(2008)
Nat Clin Pract Urol
, vol.5
, pp. 610-620
-
-
Reid, A.H.1
Attard, G.2
Barrie, E.3
de Bono, J.S.4
-
285
-
-
67650726486
-
Multiple myeloma
-
19541364,; PMID
-
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374:324-39; PMID:19541364; http://dx.doi.org/10.1016/S0140-6736(09)60221-X
-
(2009)
Lancet
, vol.374
, pp. 324-339
-
-
Raab, M.S.1
Podar, K.2
Breitkreutz, I.3
Richardson, P.G.4
Anderson, K.C.5
-
286
-
-
0001318929
-
The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas
-
13402792,; PMID
-
Ranney HM, Gellhorn A. The effect of massive prednisone and prednisolone therapy on acute leukemia and malignant lymphomas. Am J Med 1957; 22:405-13; PMID:13402792; http://dx.doi.org/10.1016/0002-9343(57)90096-7
-
(1957)
Am J Med
, vol.22
, pp. 405-413
-
-
Ranney, H.M.1
Gellhorn, A.2
-
287
-
-
84899809126
-
Degarelix: a review of its use in patients with prostate cancer
-
24756432,; PMID
-
Carter NJ, Keam SJ. Degarelix: a review of its use in patients with prostate cancer. Drugs 2014; 74:699-712; PMID:24756432; http://dx.doi.org/10.1007/s40265-014-0211-y
-
(2014)
Drugs
, vol.74
, pp. 699-712
-
-
Carter, N.J.1
Keam, S.J.2
-
288
-
-
74749105209
-
Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer
-
20110043,; PMID
-
Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther 2009; 31 2:2312-31; PMID:20110043; http://dx.doi.org/10.1016/j.clinthera.2009.11.009
-
(2009)
Clin Ther
, vol.31
, Issue.2
, pp. 2312-2331
-
-
Steinberg, M.1
-
289
-
-
66849104149
-
The role of floxuridine in metastatic liver disease
-
19383854,; PMID
-
Power DG, Kemeny NE. The role of floxuridine in metastatic liver disease. Mol Cancer Ther 2009; 8:1015-25; PMID:19383854; http://dx.doi.org/10.1158/1535-7163.MCT-08-0709
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1015-1025
-
-
Power, D.G.1
Kemeny, N.E.2
-
290
-
-
21244497388
-
Capecitabine as adjuvant treatment for stage III colon cancer
-
15987918, et al.,; PMID
-
Twelves C, Wong A, Nowacki MP, Abt M, Burris H, 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696-704; PMID:15987918; http://dx.doi.org/10.1056/NEJMoa043116
-
(2005)
N Engl J Med
, vol.352
, pp. 2696-2704
-
-
Twelves, C.1
Wong, A.2
Nowacki, M.P.3
Abt, M.4
Burris, H.5
Carrato, A.6
Cassidy, J.7
Cervantes, A.8
Fagerberg, J.9
Georgoulias, V.10
-
291
-
-
13744251436
-
Systemic therapy for colorectal cancer
-
15689586,; PMID
-
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352:476-87; PMID:15689586; http://dx.doi.org/10.1056/NEJMra040958
-
(2005)
N Engl J Med
, vol.352
, pp. 476-487
-
-
Meyerhardt, J.A.1
Mayer, R.J.2
-
292
-
-
84875536112
-
Management of advanced colorectal cancer, Part 2
-
23456402,; PMID
-
Cersosimo RJ. Management of advanced colorectal cancer, Part 2. Am J Health Syst Pharm 2013; 70:491-506; PMID:23456402; http://dx.doi.org/10.2146/ajhp110532b
-
(2013)
Am J Health Syst Pharm
, vol.70
, pp. 491-506
-
-
Cersosimo, R.J.1
-
293
-
-
84874086467
-
Management of advanced colorectal cancer, Part 1
-
23413162,; PMID
-
Cersosimo RJ. Management of advanced colorectal cancer, Part 1. Am J Health Syst Pharm 2013; 70:395-406; PMID:23413162; http://dx.doi.org/10.2146/ajhp110532
-
(2013)
Am J Health Syst Pharm
, vol.70
, pp. 395-406
-
-
Cersosimo, R.J.1
-
294
-
-
0033766638
-
Oxaliplatin. a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies
-
11085200,; PMID
-
Culy CR, Clemett D, Wiseman LR. Oxaliplatin. a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000; 60:895-924; PMID:11085200; http://dx.doi.org/10.2165/00003495-200060040-00005
-
(2000)
Drugs
, vol.60
, pp. 895-924
-
-
Culy, C.R.1
Clemett, D.2
Wiseman, L.R.3
-
295
-
-
0036052558
-
Cellular and molecular pharmacology of oxaliplatin
-
12467217,; PMID
-
Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1:227-35; PMID:12467217
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 227-235
-
-
Raymond, E.1
Faivre, S.2
Chaney, S.3
Woynarowski, J.4
Cvitkovic, E.5
-
296
-
-
84871203961
-
High-dose etoposide in allogeneic stem cell transplantation
-
23053272,; PMID
-
Bruserud O, Reikvam H, Kittang AO, Ahmed AB, Tvedt TH, Sjo M, Hatfield KJ. High-dose etoposide in allogeneic stem cell transplantation. Cancer Chemother Pharmacol 2012; 70:765-82; PMID:23053272; http://dx.doi.org/10.1007/s00280-012-1990-z
-
(2012)
Cancer Chemother Pharmacol
, vol.70
, pp. 765-782
-
-
Bruserud, O.1
Reikvam, H.2
Kittang, A.O.3
Ahmed, A.B.4
Tvedt, T.H.5
Sjo, M.6
Hatfield, K.J.7
-
297
-
-
34248356003
-
Cellular response to etoposide treatment
-
17166655,; PMID
-
Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252:9-18; PMID:17166655; http://dx.doi.org/10.1016/j.canlet.2006.11.005
-
(2007)
Cancer Lett
, vol.252
, pp. 9-18
-
-
Montecucco, A.1
Biamonti, G.2
-
298
-
-
84885021526
-
Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring
-
24052062,; PMID
-
Josephs DH, Fisher DS, Spicer J, Flanagan RJ. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit 2013; 35:562-87; PMID:24052062
-
(2013)
Ther Drug Monit
, vol.35
, pp. 562-587
-
-
Josephs, D.H.1
Fisher, D.S.2
Spicer, J.3
Flanagan, R.J.4
-
299
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
19786658, et al.,; PMID
-
Johnston S, Pippen J, Jr., Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538-46; PMID:19786658; http://dx.doi.org/10.1200/JCO.2009.23.3734
-
(2009)
J Clin Oncol
, vol.27
, pp. 5538-5546
-
-
Johnston, S.1
Pippen, J.2
Pivot, X.3
Lichinitser, M.4
Sadeghi, S.5
Dieras, V.6
Gomez, H.L.7
Romieu, G.8
Manikhas, A.9
Kennedy, M.J.10
-
300
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
17192538, et al.,; PMID
-
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-43; PMID:17192538; http://dx.doi.org/10.1056/NEJMoa064320
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
-
301
-
-
32944461545
-
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
-
16452222, et al.,; PMID
-
Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66:1630-9; PMID:16452222; http://dx.doi.org/10.1158/0008-5472.CAN-05-1182
-
(2006)
Cancer Res
, vol.66
, pp. 1630-1639
-
-
Konecny, G.E.1
Pegram, M.D.2
Venkatesan, N.3
Finn, R.4
Yang, G.5
Rahmeh, M.6
Untch, M.7
Rusnak, D.W.8
Spehar, G.9
Mullin, R.J.10
-
302
-
-
84881519427
-
Resistance to PARP-Inhibitors in Cancer Therapy
-
23450678,; PMID
-
Montoni A, Robu M, Pouliot E, Shah GM. Resistance to PARP-Inhibitors in Cancer Therapy. Front Pharmacol 2013; 4:18; PMID:23450678; http://dx.doi.org/10.3389/fphar.2013.00018
-
(2013)
Front Pharmacol
, vol.4
, pp. 18
-
-
Montoni, A.1
Robu, M.2
Pouliot, E.3
Shah, G.M.4
-
303
-
-
84872971914
-
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
-
23165508, et al.,; PMID
-
Barber LJ, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K, Assiotis I, Rodrigues DN, Reis Filho JS, Moreno V, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 2013; 229:422-9; PMID:23165508; http://dx.doi.org/10.1002/path.4140
-
(2013)
J Pathol
, vol.229
, pp. 422-429
-
-
Barber, L.J.1
Sandhu, S.2
Chen, L.3
Campbell, J.4
Kozarewa, I.5
Fenwick, K.6
Assiotis, I.7
Rodrigues, D.N.8
Reis Filho, J.S.9
Moreno, V.10
-
304
-
-
39849097680
-
Resistance to therapy caused by intragenic deletion in BRCA2
-
18264088,; PMID
-
Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451:1111-5; PMID:18264088; http://dx.doi.org/10.1038/nature06548
-
(2008)
Nature
, vol.451
, pp. 1111-1115
-
-
Edwards, S.L.1
Brough, R.2
Lord, C.J.3
Natrajan, R.4
Vatcheva, R.5
Levine, D.A.6
Boyd, J.7
Reis-Filho, J.S.8
Ashworth, A.9
-
305
-
-
84872837247
-
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
-
23103855, et al.,; PMID
-
Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013; 3:68-81; PMID:23103855; http://dx.doi.org/10.1158/2159-8290.CD-12-0049
-
(2013)
Cancer Discov
, vol.3
, pp. 68-81
-
-
Jaspers, J.E.1
Kersbergen, A.2
Boon, U.3
Sol, W.4
van Deemter, L.5
Zander, S.A.6
Drost, R.7
Wientjens, E.8
Ji, J.9
Aly, A.10
-
306
-
-
77950958141
-
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks
-
20362325, et al.,; PMID
-
Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141:243-54; PMID:20362325; http://dx.doi.org/10.1016/j.cell.2010.03.012
-
(2010)
Cell
, vol.141
, pp. 243-254
-
-
Bunting, S.F.1
Callen, E.2
Wong, N.3
Chen, H.T.4
Polato, F.5
Gunn, A.6
Bothmer, A.7
Feldhahn, N.8
Fernandez-Capetillo, O.9
Cao, L.10
-
307
-
-
84930678981
-
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
-
25799992, et al.,; PMID
-
Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015; PMID:25799992
-
(2015)
Nature
-
-
Xu, G.1
Chapman, J.R.2
Brandsma, I.3
Yuan, J.4
Mistrik, M.5
Bouwman, P.6
Bartkova, J.7
Gogola, E.8
Warmerdam, D.9
Barazas, M.10
-
308
-
-
55949092708
-
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
-
18971340, et al.,; PMID
-
Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105:17079-84; PMID:18971340; http://dx.doi.org/10.1073/pnas.0806092105
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 17079-17084
-
-
Rottenberg, S.1
Jaspers, J.E.2
Kersbergen, A.3
van der Burg, E.4
Nygren, A.O.5
Zander, S.A.6
Derksen, P.W.7
de Bruin, M.8
Zevenhoven, J.9
Lau, A.10
-
309
-
-
79955957616
-
Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm
-
21596313,; PMID
-
Leung AK, Vyas S, Rood JE, Bhutkar A, Sharp PA, Chang P. Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol Cell 2011; 42:489-99; PMID:21596313; http://dx.doi.org/10.1016/j.molcel.2011.04.015
-
(2011)
Mol Cell
, vol.42
, pp. 489-499
-
-
Leung, A.K.1
Vyas, S.2
Rood, J.E.3
Bhutkar, A.4
Sharp, P.A.5
Chang, P.6
-
310
-
-
84907212907
-
Cell biology. Metabolic control of cell death
-
25237106,; PMID
-
Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell death. Science 2014; 345:1250256; PMID:25237106; http://dx.doi.org/10.1126/science.1250256
-
(2014)
Science
, vol.345
, pp. 1250256
-
-
Green, D.R.1
Galluzzi, L.2
Kroemer, G.3
-
311
-
-
0037379179
-
Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function
-
12640128,; PMID
-
Kanai M, Tong WM, Sugihara E, Wang ZQ, Fukasawa K, Miwa M. Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function. Mol Cell Biol 2003; 23:2451-62; PMID:12640128; http://dx.doi.org/10.1128/MCB.23.7.2451-2462.2003
-
(2003)
Mol Cell Biol
, vol.23
, pp. 2451-2462
-
-
Kanai, M.1
Tong, W.M.2
Sugihara, E.3
Wang, Z.Q.4
Fukasawa, K.5
Miwa, M.6
-
312
-
-
34250198661
-
Haploinsufficiency of poly(ADP-ribose) polymerase-1-mediated poly(ADP-ribosyl)ation for centrosome duplication
-
17553458,; PMID
-
Kanai M, Tong WM, Wang ZQ, Miwa M. Haploinsufficiency of poly(ADP-ribose) polymerase-1-mediated poly(ADP-ribosyl)ation for centrosome duplication. Biochem Biophys Res Commun 2007; 359:426-30; PMID:17553458; http://dx.doi.org/10.1016/j.bbrc.2007.05.108
-
(2007)
Biochem Biophys Res Commun
, vol.359
, pp. 426-430
-
-
Kanai, M.1
Tong, W.M.2
Wang, Z.Q.3
Miwa, M.4
-
313
-
-
0034633783
-
Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase
-
11016956,; PMID
-
Simbulan-Rosenthal CM, Ly DH, Rosenthal DS, Konopka G, Luo R, Wang ZQ, Schultz PG, Smulson ME. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A 2000; 97:11274-9; PMID:11016956; http://dx.doi.org/10.1073/pnas.200285797
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 11274-11279
-
-
Simbulan-Rosenthal, C.M.1
Ly, D.H.2
Rosenthal, D.S.3
Konopka, G.4
Luo, R.5
Wang, Z.Q.6
Schultz, P.G.7
Smulson, M.E.8
-
314
-
-
16544373283
-
Defective control of mitotic and post-mitotic checkpoints in poly(ADP-ribose) polymerase-1(−/−) fibroblasts after mitotic spindle disruption
-
14726664,; PMID
-
Halappanavar SS, Shah GM. Defective control of mitotic and post-mitotic checkpoints in poly(ADP-ribose) polymerase-1(−/−) fibroblasts after mitotic spindle disruption. Cell Cycle 2004; 3:335-42; PMID:14726664; http://dx.doi.org/10.4161/cc.3.3.670
-
(2004)
Cell Cycle
, vol.3
, pp. 335-342
-
-
Halappanavar, S.S.1
Shah, G.M.2
-
315
-
-
84867397184
-
Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation
-
22955851,; PMID
-
Inbar D, Cohen-Armon M, Neumann D. Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation. Br J Cancer 2012; 107:1317-26; PMID:22955851; http://dx.doi.org/10.1038/bjc.2012.395
-
(2012)
Br J Cancer
, vol.107
, pp. 1317-1326
-
-
Inbar, D.1
Cohen-Armon, M.2
Neumann, D.3
-
316
-
-
84858178110
-
Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, stimulate angiogenesis by regulating expression of urokinase type plasminogen activator and matrix metalloprotease 2
-
21595892,; PMID
-
Caldini R, Fanti E, Magnelli L, Barletta E, Tanganelli E, Zampieri M, Chevanne M. Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, stimulate angiogenesis by regulating expression of urokinase type plasminogen activator and matrix metalloprotease 2. Vasc Cell 2011; 3:12; PMID:21595892; http://dx.doi.org/10.1186/2045-824X-3-12
-
(2011)
Vasc Cell
, vol.3
, pp. 12
-
-
Caldini, R.1
Fanti, E.2
Magnelli, L.3
Barletta, E.4
Tanganelli, E.5
Zampieri, M.6
Chevanne, M.7
-
317
-
-
64549160302
-
Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells
-
19212692,; PMID
-
Lacal PM, Tentori L, Muzi A, Ruffini F, Dorio AS, Xu W, Arcelli D, Zhang J, Graziani G. Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Int J Oncol 2009; 34:861-72; PMID:19212692
-
(2009)
Int J Oncol
, vol.34
, pp. 861-872
-
-
Lacal, P.M.1
Tentori, L.2
Muzi, A.3
Ruffini, F.4
Dorio, A.S.5
Xu, W.6
Arcelli, D.7
Zhang, J.8
Graziani, G.9
-
318
-
-
34548514842
-
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
-
17714938, et al.,; PMID
-
Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M, Ruffini F, Xu W, Min W, Stoppacciaro A, et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 2007; 43:2124-33; PMID:17714938; http://dx.doi.org/10.1016/j.ejca.2007.07.010
-
(2007)
Eur J Cancer
, vol.43
, pp. 2124-2133
-
-
Tentori, L.1
Lacal, P.M.2
Muzi, A.3
Dorio, A.S.4
Leonetti, C.5
Scarsella, M.6
Ruffini, F.7
Xu, W.8
Min, W.9
Stoppacciaro, A.10
-
319
-
-
46749119301
-
Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34
-
18575783,; PMID
-
Pyriochou A, Olah G, Deitch EA, Szabo C, Papapetropoulos A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med 2008; 22:113-8; PMID:18575783
-
(2008)
Int J Mol Med
, vol.22
, pp. 113-118
-
-
Pyriochou, A.1
Olah, G.2
Deitch, E.A.3
Szabo, C.4
Papapetropoulos, A.5
-
320
-
-
33750046338
-
Poly(ADP-ribose)polymerase inhibition decreases angiogenesis
-
17046715,; PMID
-
Rajesh M, Mukhopadhyay P, Godlewski G, Batkai S, Hasko G, Liaudet L, Pacher P. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem Biophys Res Commun 2006; 350:1056-62; PMID:17046715; http://dx.doi.org/10.1016/j.bbrc.2006.09.160
-
(2006)
Biochem Biophys Res Commun
, vol.350
, pp. 1056-1062
-
-
Rajesh, M.1
Mukhopadhyay, P.2
Godlewski, G.3
Batkai, S.4
Hasko, G.5
Liaudet, L.6
Pacher, P.7
-
321
-
-
84859892610
-
RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway
-
22508044,; PMID
-
Li Q, Li M, Wang YL, Fauzee NJ, Yang Y, Pan J, Yang L, Lazar A. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. Cell Physiol Biochem 2012; 29:361-72; PMID:22508044; http://dx.doi.org/10.1159/000338491
-
(2012)
Cell Physiol Biochem
, vol.29
, pp. 361-372
-
-
Li, Q.1
Li, M.2
Wang, Y.L.3
Fauzee, N.J.4
Yang, Y.5
Pan, J.6
Yang, L.7
Lazar, A.8
-
322
-
-
84870855799
-
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
-
23197039,; PMID
-
Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 2012; 11:923-36; PMID:23197039; http://dx.doi.org/10.1038/nrd3868
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 923-936
-
-
Riffell, J.L.1
Lord, C.J.2
Ashworth, A.3
-
323
-
-
70449102637
-
A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation
-
19917246,; PMID
-
Stilmann M, Hinz M, Arslan SC, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation. Mol Cell 2009; 36:365-78; PMID:19917246; http://dx.doi.org/10.1016/j.molcel.2009.09.032
-
(2009)
Mol Cell
, vol.36
, pp. 365-378
-
-
Stilmann, M.1
Hinz, M.2
Arslan, S.C.3
Zimmer, A.4
Schreiber, V.5
Scheidereit, C.6
-
324
-
-
33846362869
-
DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation
-
17244536,; PMID
-
Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, Klein R, Bendetz-Nezer S, Yao Z, Seger R. DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell 2007; 25:297-308; PMID:17244536; http://dx.doi.org/10.1016/j.molcel.2006.12.012
-
(2007)
Mol Cell
, vol.25
, pp. 297-308
-
-
Cohen-Armon, M.1
Visochek, L.2
Rozensal, D.3
Kalal, A.4
Geistrikh, I.5
Klein, R.6
Bendetz-Nezer, S.7
Yao, Z.8
Seger, R.9
-
325
-
-
33646481320
-
Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2
-
16627622,; PMID
-
Kauppinen TM, Chan WY, Suh SW, Wiggins AK, Huang EJ, Swanson RA. Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. Proc Natl Acad Sci U S A 2006; 103:7136-41; PMID:16627622; http://dx.doi.org/10.1073/pnas.0508606103
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 7136-7141
-
-
Kauppinen, T.M.1
Chan, W.Y.2
Suh, S.W.3
Wiggins, A.K.4
Huang, E.J.5
Swanson, R.A.6
-
326
-
-
84891556827
-
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells
-
22454224,; PMID
-
Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. Breast Cancer 2014; 21:75-85; PMID:22454224; http://dx.doi.org/10.1007/s12282-012-0356-z
-
(2014)
Breast Cancer
, vol.21
, pp. 75-85
-
-
Shimo, T.1
Kurebayashi, J.2
Kanomata, N.3
Yamashita, T.4
Kozuka, Y.5
Moriya, T.6
Sonoo, H.7
-
327
-
-
84869094697
-
PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1alpha-mediated unfolded protein response
-
23103912,; PMID
-
Jwa M, Chang P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1alpha-mediated unfolded protein response. Nat Cell Biol 2012; 14:1223-30; PMID:23103912; http://dx.doi.org/10.1038/ncb2593
-
(2012)
Nat Cell Biol
, vol.14
, pp. 1223-1230
-
-
Jwa, M.1
Chang, P.2
-
328
-
-
84921911496
-
Activation of poly(ADP-ribose) polymerase-1 delays wound healing by regulating keratinocyte migration and production of inflammatory mediators
-
25014793,; PMID
-
El-Hamoly T, Hegedus C, Lakatos P, Kovacs K, Bai P, El-Ghazaly MA, El-Denshary ES, Szabo E, Virag L. Activation of poly(ADP-ribose) polymerase-1 delays wound healing by regulating keratinocyte migration and production of inflammatory mediators. Mol Med 2014; 20:363-71; PMID:25014793; http://dx.doi.org/10.2119/molmed.2014.00130
-
(2014)
Mol Med
, vol.20
, pp. 363-371
-
-
El-Hamoly, T.1
Hegedus, C.2
Lakatos, P.3
Kovacs, K.4
Bai, P.5
El-Ghazaly, M.A.6
El-Denshary, E.S.7
Szabo, E.8
Virag, L.9
-
329
-
-
84926453964
-
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
-
25573533,; 26:804-11; PMID
-
Bendell J, O'Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H, 3rd. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Ann Oncol 2015; 26:804-11; PMID:25573533; http://dx.doi.org/10.1093/annonc/mdu581
-
(2015)
Ann Oncol
-
-
Bendell, J.1
O'Reilly, E.M.2
Middleton, M.R.3
Chau, I.4
Hochster, H.5
Fielding, A.6
Burke, W.7
Burris, H.8
-
330
-
-
66849106010
-
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies
-
19364967, et al.,; PMID
-
Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009; 27:2705-11; PMID:19364967; http://dx.doi.org/10.1200/JCO.2008.19.7681
-
(2009)
J Clin Oncol
, vol.27
, pp. 2705-2711
-
-
Kummar, S.1
Kinders, R.2
Gutierrez, M.E.3
Rubinstein, L.4
Parchment, R.E.5
Phillips, L.R.6
Ji, J.7
Monks, A.8
Low, J.A.9
Chen, A.10
|